VAV1-targeted degrader and use thereof

Abstract

The present invention relates to a VAV1-targeted degrader and the use thereof. In particular, the present invention relates to a compound as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating / preventing VAV1-mediated diseases, wherein each substituent in general formula (I) is the same as defined in the description.

Description

VAV1 Targeted Degraders and Their Uses Technical Field

[0001] This invention relates to a VAV1-targeting degrader, its stereoisomer, a pharmaceutically acceptable salt, and its use in the preparation of medicaments for treating VAV1-mediated related diseases. Background Technology

[0002] Molecular glues are a class of small molecules that influence protein function by inducing proximity between target proteins and effector macromolecules, thereby altering protein-protein interactions. The main mechanism of action of molecular glues involves inducing proximity between target proteins and ubiquitin ligases, ensuring the successful degradation of the target protein by the ubiquitin-proteasome system.

[0003] The VAV family is a group of signal transduction proteins that serve as phosphorylation-dependent GDP / GTP exchange factors (GEFs) and adaptor molecules for Rho subfamily GTPases. It consists of three members: VAV1, VAV2, and VAV3. VAV1, a member of the VAV family, is primarily expressed in human hematopoietic stem cells, including T cells, B cells, monocytes, natural killer (NK) cells, granulocytes, and dendritic cells. As a bifunctional protein, VAV1 possesses both GEF activity and scaffold protein function. By degrading VAV1 protein, VAV1 molecules can simultaneously inhibit its GEF activity and scaffold protein function, thereby blocking multiple important signaling pathways of T cells and B cells, more comprehensively suppressing immune responses, and reducing inflammation or autoimmune activity.

[0004] Currently, treatment options for autoimmune diseases and chronic inflammatory diseases remain limited. VAV1 molecular gel has a unique mechanism and broad potential applications. It can be safely administered orally to treat a variety of autoimmune diseases (multiple sclerosis, rheumatoid arthritis, ulcerative colitis, myasthenia gravis, chronic lymphocytic leukemia, psoriasis, cutaneous lupus, axial spondylitis, and graft-versus-host disease, etc.), thus meeting unmet clinical needs. Summary of the Invention

[0005] This invention provides a compound of VAV1-targeting degrader, its stereoisomer or a pharmaceutically acceptable salt thereof, its preparation method, intermediates, and applications. Specifically, this invention provides a compound of general formula (I), its preparation method, intermediates, a pharmaceutical composition comprising the compound of general formula (I), and the application of the compound of general formula (I) or a pharmaceutical composition thereof in the preparation of a medicament for treating / preventing VAV1-mediated diseases. The compound exhibits excellent activity, superior physicochemical properties, ease of formulation, high bioavailability, and low toxicity.

[0006] This invention provides a compound of formula (I), formula (II), formula (III), formula (VI), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (IX-1), and formula (IV-1), its stereoisomer or pharmaceutically acceptable salt,

[0007] in,

[0008] The ring C is selected from a bonded carbon ring, a 3-15 membered carbon ring, or a 4-15 membered heterocycle. When the ring C is selected from a bonded carbon ring, R... C Directly connected to L2;

[0009] In some embodiments, ring C is selected from 3-15 membered carbon rings or 4-15 membered heterocycles;

[0010] In some embodiments, cyclic C is selected from 5-10 membered heteroaryl groups;

[0011] In some embodiments, the cyclic C is selected from 5-6 membered heteroaryl or 8-10 membered heteroaryl;

[0012] In some embodiments, cyclic C is selected from 5-6 membered heteroaryl groups;

[0013] In some embodiments, the ring C is selected from cycloalkyl, 3-6-membered cycloalkyl, 4-8-membered heterocycloalkyl, 7-11-bicyclic heterocyclic, 7-12-tricyclic heterocyclic, 5-6-heteroaryl, and 6-8-membered aryl.

[0014] In some embodiments, the ring C is selected from bonds, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 7-11 bicyclic heterocyclic, 7-11 tricyclic heterocyclic, 5-6 heteroaryl, and 6-8 membered aryl;

[0015] In some embodiments, ring C is selected from 7-11 bicyclic heterocyclic groups and 5-6 heteroaryl groups;

[0016] In some embodiments, the cyclic C is selected from 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, and 5-6 heteroaryl;

[0017] In some embodiments, the ring C is selected from 3-, 4-, 5-, 6-membered cycloalkyl, or 4-, 5-, 6-, 7-, 8-membered heterocycloalkyl, or 5-membered heteroaryl or 6-membered heteroaryl;

[0018] In some embodiments, the ring C is selected from 4, 5, 6, 7, 8-membered heterocyclic alkyl, or 5-membered heteroaryl, 6-membered heteroaryl, or 9-membered bicyclic heteroaryl, 10-membered bicyclic heteroaryl, 8-membered bicyclic heterocyclic alkyl, 9-membered bicyclic heterocyclic alkyl, 10-membered bicyclic heterocyclic alkyl;

[0019] In some embodiments, the cyclic C is selected from 5-membered heteroaryl, 6-membered heteroaryl, 9-membered bicyclic heteroaryl, 6-membered heteroaryl and 5-membered cycloalkyl;

[0020] In some embodiments, the cyclic C is selected from the following groups: cyclobutenyl,

[0021] In some embodiments, the cyclic C is selected from the following groups: cyclobutenyl, Or selected from

[0022] In some implementations, Selected from

[0023] In some implementation schemes, Selected from

[0024] In some implementations, Selected from

[0025] In some implementations, ring C is selected from 1-3 rings selected from R. C The following groups are substituted:

[0026] In some implementations, ring C is selected from 1-3 rings selected from R. C The following groups are substituted:

[0027] In some implementations, ring C is selected from R C1 The following groups are substituted:

[0028] In some implementations, ring C is selected from 1-3 rings selected from R. C The following groups are substituted:

[0029] In some embodiments, cyclic C is selected from 5-10 membered heteroaryl groups;

[0030] In some embodiments, cyclic C is selected from 5-6 membered heteroaryl groups;

[0031] In some embodiments, the cyclic C is selected from the following groups:

[0032] Each R C Each is independently selected from halogens, =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, C 2-6 alkenyl, C 2-6 alkynyl group, -C 1-3 Alkyl-NRy-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 Cycloalkyl, 5-6 membered heteroaryl, -C(=S)NR y -C 3-8 cycloalkyl, -C(=S)NH-C 3-8 cycloalkyl, =NC 3-8 Cycloalkyl, -NH- (4-8 membered heterocycloalkyl), -NR y -(4-8 membered heterocyclic alkyl groups), or C 1-6 Halogenated alkyl groups, -NH- (5-6 membered heteroaryl groups), -NR y -(5-6-membered heteroaryl), wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0033] Ra and Rb are each independently selected from hydrogen, deuterium, cyano, and C. 1-6 Alkyl, C 1-6 alkoxy groups, wherein the alkyl or alkoxy group is optionally further surrounded by 1-5 R groups. x Replaced;

[0034] In some embodiments, Ra and Rb are each independently selected from hydrogen, cyano, and C. 1-4 Alkyl, C 1-4 alkoxy groups, wherein the alkyl or alkoxy group is optionally further surrounded by 1-5 R groups. x Replaced;

[0035] In some implementations, each R CEach is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 cycloalkyl or C 2-6 alkenyl, or C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl groups, -NH- (5-6 membered heteroaryl groups), -NR y -(5-6-membered heteroaryl), wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl is optionally further surrounded by 1-5 R x Replaced;

[0036] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, CN, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl)2, -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further divided by 1-5 R x Replaced;

[0037] R y Selected from D and C 1-4 Alkyl, C 1-4 Alkoxy, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, C 3-6 cycloalkyl;

[0038] In some implementations, R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-6 cycloalkyl;

[0039] In some implementations, R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-4 cycloalkyl;

[0040] In some implementations, R y Selected from C 1-2 Alkyl, cyclopropyl;

[0041] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)-C 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHC(=O)- (4-6 membered heterocyclic alkyl), -C(=O)NH- (4-6 membered heterocyclic alkyl), -NHSO2- (4-6 membered heterocyclic alkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-6 cycloalkyl, -C 1-3 Alkyl-OC 3-6 cycloalkyl, -C 1-3Alkyl-(4-6-membered heterocyclic alkyl), -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, heterocyclic alkyl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0042] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C(=O)NH- (5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, or NH2 may optionally be further surrounded by 1-5 R x Replaced;

[0043] In some implementations, each RC Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C(=O)NH- (5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, or NH2 may optionally be further surrounded by 1-5 R x Replaced;

[0044] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, -NHSO2NH2, CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C(=O)NH- (5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, or NH2 may optionally be further surrounded by 1-5 R x Replaced;

[0045] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -Cy3 -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0046] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0047] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, -NHSO2NH2, CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -C y1 -C y2 -C y3 -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0048] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, C 1-6 Alkyl, CN, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy groups, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocycloalkyl), -C(=O)NH- (4-8 membered heterocycloalkyl), -C y1 -C y2 -C y3 -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0049] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, CN, C 1-6 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C)1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 cycloalkyl, -C y1 -C y2 -C y3 -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0050] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, CN, C 1-4 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl, -C y1 -C y2 -C y3 -C(=O)NH-(5-6-membered heteroaryl), wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0051] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -C(=O)NH- (5-6-membered heteroaryl), wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0052] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -Cy1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -SO2NH-C 3-6 cycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C(=O)NH-(5-6-membered heteroaryl) or 5-6-membered heteroaryl, C 2-4 alkenyl, or C 2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl is optionally further surrounded by 1-5 R x Replaced;

[0053] In some implementations, R C Selected from C 1-4 Alkyl, CN, C 1-4 Halogenated alkyl, 3-6 membered cycloalkyl, halogen, C 2-4 alkynyl group, C 2-4 alkenyl, C 1-4 Alkoxy, 5-6 membered heteroaryl, C 1-4 Deuterated alkyl or 5-6 membered heterocyclic alkyl, wherein the cycloalkyl, heteroaryl, or heterocyclic alkyl group is optionally further selected from 1-3 elements selected from =O, deuterium, CN, halogen, hydroxyl, C. 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Substitution of deuterated alkyl groups;

[0054] In some implementations, R C Selected from CN, C 1-4 Alkyl, C 1-4 Alkoxy, -C 1-4 Haloalkoxy group, -C(=O)NH-C 3-6cycloalkyl, -NHC(=O)-C 3-6 Cycloalkyl, -CONH-(5-6 heteroaryl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, halogen, 5-6 membered heteroaryl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, -O- (3-6 membered cycloalkyl), -N=S (=O) (C 1-3 Alkyl)2, -NHSO2- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -C(=O)NR y -C 3-6 cycloalkyl, -SO2-C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6 membered heteroaryl), -C(=O)-(4-6 membered heterocyclic alkyl), -NH-C 3-6 cycloalkyl, -SO2NH-C 3-6 Cycloalkyl, -C(=O)-(5-6-membered heteroaryl), -NH-(5-6-membered heteroaryl), -C(=O)-C 3-6 Cycloalkyl, -O-(5-6-membered heteroaryl), =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, or alkynyl group is optionally further selected from 1-4 C 1-2 Alkyl, C 1-2 Haloalkyl, =O, halogen, 3-4 membered cycloalkyl, C 1-2 Deuterated alkyl, C 1-2 Alkoxy, C 1-2 Substitution of alkyl halogens, =CH2, =CF2, =C(CH3)2 groups;

[0055] In some implementations, R C Selected from CN, C 1-4 Alkyl, C 1-4 Alkoxy group, -C(=O)NH-C 3-6 cycloalkyl, -NHC(=O)-C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, halogen, 5-6 membered heteroaryl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, or alkynyl group is optionally further selected from 1 to 4 C14 groups. 1-2 Alkyl, C 1-2Haloalkyl, =O, halogen, 3-4 membered cycloalkyl, C 1-2 Deuterated alkyl, C 1-2 Alkoxy, C 1-2 Substitution of alkyl halogens, =CH2, =CF2, =C(CH3)2 groups;

[0056] In some implementations, R C Selected from CN, C 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Halogenated alkyl groups, halogens, 3-4 membered cycloalkyl groups, C 1-2 Deuterated alkyl, C 2-3 alkenyl, C 2-3 Alkyne group, 5-6 heteroaryl group, wherein the cycloalkyl group or heteroaryl group is optionally further selected from 1-3 groups selected from deuterium, CN, halogen, hydroxyl, C 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Deuterated alkyl groups are substituted; in some embodiments, R C Selected from F, Cl, =O, =S, =NH, -SF5, -SCF3, -NHSO2NH2, CN, =CH2, =CF2, =CHF, -OCHF2, -OCF3, methyl, ethyl, methoxy, ethoxy, isopropyl, -O-cyclopropyl, -C(O)-azacyclobutyl, -NHC(=O)-cyclopropyl, -C(=O)NH-cyclopropyl, -ethynyl-CN, -NH-cyclopropyl, -N(CH3)-cyclopropyl, -NHSO2-(azacyclobutyl), -NHSO2-(azacyclopentyl), -S(=O)(=NH)-CH3, -N=S(=O)(CH3)2, -P(=O)(CH3)2, -P(=O)(OC 1-2 Alkyl)2, -NH-SO2-CH3, -NH-SO2-NHCH3, methanesulfonyl, -SO2NH-cyclopropyl, -CH2-O-cyclopropyl, -CH(CH3)-cyclopropyl, -CH(CH3)-azacyclobutyl, =N-cyclopropyl, Acetylene group, CF3, Cyclopropyl, -C(=O)-cyclopropyl, -C(=O)O-cyclopropylCN, cyclopentyl, -SO2NHC(=O)O-CH3、-C(=O)NHSO2-cyclopropyl、 Vinyl, CHF2, CD3 propyne group, -CH(CH3)2、

[0057] In some implementations, R C Selected from C 1-4 Alkyl, CN, C 1-4 Halogenated alkyl groups, 3-6 membered cycloalkyl groups;

[0058] In some implementations, R C Selected from -CH3, -CHF2, -CH2F, -CF3, -F, -Cl, -CD3, and cyclopropyl;

[0059] C y1 C y2 C y3 Each cycloalkyl group is independently selected from 3-8-membered cycloalkyl, 4-10-membered heterocycloalkyl, 5-6-heteroaryl, and 6-8-membered aryl, wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0060] In some implementations, C y1 C y2 C y3 Each member is independently selected from 4-10-membered heterocyclic alkyl, 5-6-heteroaryl, or 6-8-membered aryl, wherein the heterocyclic alkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0061] In some implementations, C y1 C y2 C y3 Each member is independently selected from 4-6-membered heterocyclic alkyl, 5-6-heteroaryl, or 6-8-membered aryl, wherein the heterocyclic alkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0062] In some implementations, C y1 C y2 C y3 Each member is independently selected from 5-6-membered heterocyclic alkyl, 5-6-heteroaryl, and 6-membered aryl, wherein the heterocyclic alkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0063] In some implementations, C y1 Selected from 5-6 heteroaryl and 6-membered aryl groups, wherein the aryl or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0064] In some implementations, C y1 Selected from 1-3 Rs x The following groups are substituted:

[0065] In some implementations, C y2 Selected from 6-membered aryl groups, wherein the aryl group is optionally further divided by 1-5 R groups. x Replaced;

[0066] In some implementations, C y2 Selected from 1-3 Rs x The following groups are substituted:

[0067] In some implementations, C y3 Selected from 5-6 membered heterocyclic alkyl groups and 6 membered aryl groups, wherein the aryl or heterocyclic alkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0068] In some implementations, C y3 Selected from 1-3 Rs x The following groups are substituted:

[0069] In some implementations, -C y1 -C y2 -C y3 Selected from 1-3 Rs x The following groups are substituted:

[0070] In some implementations, each R C Each is independently selected from =O, =S, =NH, -SF5, -SCF3, C 1-6 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy groups, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), wherein the alkoxy, alkynyl, cycloalkyl, or heterocyclic alkyl may optionally be further surrounded by 1-5 R groups. x Replaced;

[0071] In some implementations, each R C Each is independently selected from =O, =S, =NH, -SF5, -SCF3, C 1-6 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0072] In some implementations, each R C Each is independently selected from =O, =S, =NH, -SCF3, C 1-4 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0073] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 cycloalkyl, -C(=S)NH-C 3-8 cycloalkyl, =NC 3-8 Cycloalkyl, -NH- (4-8 membered heterocycloalkyl), -NR y -(4-8 membered heterocyclic alkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6 heteroaryl groups), -NH-C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0074] In some implementations, RC1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocyclic alkyl), 4-6 membered heterocyclic alkyl, -SO2NH-C 3-6 Cycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 cycloalkyl, -C(=S)NH-C3-8 Cycloalkyl, -NH- (4-6 membered heterocycloalkyl), -NR y -(4-6-membered heterocyclic alkyl), wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocyclic alkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0075] In some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-6 cycloalkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-6 cycloalkyl, -C 2-4 alkenyl-C 3-6 Cycloalkanes, -CH2-NRy-C 3-6 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-6 cycloalkyl, =NC 3-6 cycloalkyl, -CH2-NH-C 3-6 cycloalkyl, -C(=S)NH-C 3-6 Cycloalkyl, -NH- (4-6 membered heterocycloalkyl), -NR y -(4-6 membered heterocyclic alkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6 heteroaryl groups), -C(=O)NR y -C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH, CH2 optionally are further surrounded by 1-5 R x Replaced, or R C1 Selected from 1-2 of the following: =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 3-8 membered cycloalkyl groups substituted with a haloalkyl group;

[0076] In some implementations, R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R groups. x Replaced;

[0077] In some implementations, R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, and NH are optionally further modified by 1-5 R groups. x Replaced;

[0078] In some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0079] In some implementations, R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocyclic alkyl), 4-6 membered heterocyclic alkyl, -SO2NH-C 3-6 Cycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, and NH are optionally further modified by 1-5 R groups. x Replaced;

[0080] In some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC3-6 cycloalkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl) or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, and NH groups are optionally further surrounded by 1-5 R groups. x Replaced, or R C1 Selected from 1-2 of the following: =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 3-8 membered cycloalkyl groups substituted with a haloalkyl group;

[0081] In some implementations, R C1 Selected from =S, =NH, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0082] In some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 cycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0083] In some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0084] In some implementations, R C1 Selected from =S, =NH, -SCF3, C 2-4 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0085] In some implementations, each R C1 Each is independently selected from =S, =NH, -SF5, -SCF3, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0086] In some implementations, each R C1 Each is independently selected from =S, =NH, -SCF3, and C. 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, wherein the alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0087] In some implementations, R C1 Selected from -OCHF2, -OCF3, -SCF3, -SCF3, -NHSO2NH2, -S(=O)(=NH)-CH3, -N=S(=O)(CH3)2, -P(=O)(CH3)2, -C(=O)NH-CH2-CN, -C(=O)NH-CH(CH3)-CF3, -S(=O)2-NH-C(=O)O-CH3, -C(=O)NH-CN,

[0088] In some implementations, R C1 Selected from -C 1-2 Haloalkoxy, -O- (3-4 membered cycloalkyl), -CONH- (3-6 cycloalkyl), -CONH- (5-6 heteroaryl), -NHC(=O)-C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -N=S(=O)(C 1-3 Alkyl)2, -NHSO2- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -C(=O)NR y -C 3-6 cycloalkyl, -SO2-C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6 membered heteroaryl), -C(=O)-(4-6 membered heterocyclic alkyl), -NH-C 3-6 cycloalkyl, -SO2NH-C 3-6Cycloalkyl, -C(=O)-(5-6-membered heteroaryl), -NH-(5-6-membered heteroaryl), -C(=O)-C 3-6 Cycloalkyl, -O- (5-6-membered heteroaryl), wherein the cycloalkyl, heterocycloalkyl, or heteroaryl group is optionally further selected from 1-3 elements selected from deuterium, CN, halogen, hydroxyl, or C. 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Substitution with deuterated alkyl groups, =CH2, =CF2, =C(CH3)2, =(4-6 membered heterocyclic alkyl) groups;

[0089] In some implementations, R C1 Selected from -C 1-2 The cycloalkoxy group, -O- (3-4 membered cycloalkyl), -CONH- (3-6 cycloalkyl), -CONH- (5-6 heteroaryl), wherein the cycloalkyl or heteroaryl group is optionally further selected from 1-3 elements selected from deuterium, CN, halogen, hydroxyl, C 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Substitution with deuterated alkyl groups, =CH2, =CF2, =C(CH3)2 groups;

[0090] In some implementations, R C1 Selected from -OCHF2, -OCF3,

[0091] L2 is selected from the bond, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR L2 -SO2-、-NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-,-N(SO2-C 3-8 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH-, -OC(=O)-, -C(=O)-NR y -、-OC(=O)-NR y -、-SO2-NR y -, wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0092] In some implementations, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 1-3 Alkyl)-, -N(SO2-C 3-8cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH-, -OC(=O)-, -C(=O)-NR y -、-OC(=O)-NR y -、-SO2-NR y -, wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0093] In some implementations, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)-, -N(SO2-C 3-8 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH- or -OC(=O)-, wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH is optionally surrounded by 1-5 Rs. x Replaced;

[0094] In some implementations, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 Alkyl groups -SO2-, -NH-, -NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)- or -N(SO2-C 3-8 cycloalkyl), wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0095] In some implementations, L2 is selected from key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y-C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR L2 -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)- or -N(SO2-C 3-6 cycloalkyl), wherein the alkylene, alkenylene, ynylene, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0096] In some implementations, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 (ynyl group)-, -NR y C(O)-、-NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y -SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C4-6 cycloalkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-4 Cycloalkyl-(5-6-membered heteroaryl)-, -N(5-6-membered heteroaryl)-, -N(phenyl)-, -N(-NR)- y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-、-N(C 3-6 Cycloalkyl)-, -N(4-6 membered heterocycloalkyl)-, -N(SO2-C 3-6 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH-, -OC(=O)- or -N(SO2C) 1-6 alkyl)- or -N(C 2-4 -Halogenated alkenyl), -N(SO2-4-membered heterocyclic alkyl), -N(SO2-5-membered heteroaryl), -N(C 1-4 Alkyl), wherein the alkylene, alkenylene, alkynyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH is optionally surrounded by 1-5 R. x Replaced;

[0097] In some implementations, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 (ynyl group)-, -NR y C(O)-、-NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y -SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)--N(C 1-3 alkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-4 Cycloalkyl-(5-6-membered heteroaryl)-, -N(5-6-membered heteroaryl)-, -N(phenyl)-, -N(-NR)- y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-、-N(C 3-6 Cycloalkyl)-, -N (4-6 membered heterocycloalkyl)-, wherein the alkylene, alkenylene, ynylene, alkenyl, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH is optionally surrounded by 1-5 Rs. x Replaced;

[0098] In some implementations, L2 is selected from key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-5 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 Alkyl)-SO2-, -NH-, -N=4-6 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-6 cycloalkyl)-, -N(CO-C 2-4 alkenyl)-, -N(CO-C 2-4 ynyl group)-, -N(SO2-C 2-4 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 ynyl group)-, -N(C 1-3Alkyl), wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, or -NH is optionally surrounded by 1-5 R. x Replaced;

[0099] In some implementations, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 Alkyl)-SO2-, wherein the alkylene, alkenylene, ynylene, cycloalkyl, or heterocycloalkyl group is optionally surrounded by 1-5 R groups. x Replaced;

[0100] In some implementations, L2 is selected from key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-5 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 alkyl)-SO2-, wherein the alkylene, alkenylene, or yntylide is optionally surrounded by 1-5 R... x Replaced;

[0101] In some implementations, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, -O-, -Se-, -N(C)1-3 Alkyl)-C(=O)-, -N(C 1-3 (alkyl)-SO2-;

[0102] In some implementations, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-2 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-2 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 (alkyl)-SO2-;

[0103] In some implementations, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, wherein the alkylene, alkenylene, ynylene, cycloalkyl, or heterocycloalkyl group is optionally prefixed with 1-5 R groups. x Replaced;

[0104] In some implementations, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 alkylene-, wherein the alkylene, alkenylene, or yntylide is optionally surrounded by 1-5 R- groups. x Replaced;

[0105] In some implementations, L2 is selected from key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-5 membered heterocycloalkyl, wherein the alkylene, alkenylene, or ynylene group is optionally surrounded by 1-5 R groups. x Replaced;

[0106] In some implementations, L2 is selected from key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 alkylene-, wherein the alkylene, alkenylene, or yntylide is optionally surrounded by 1-5 R- groups. x Replaced;

[0107] In some implementations, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, optionally with 1-5 Rs x Replaced;

[0108] In some implementations, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene, optionally with 1-5 R x Replaced;

[0109] In some embodiments, L2 is selected from the following groups: -CH2-, -CH(OH)-, -NH-, -CH2-C(O)-, -NHC(O)-, -N(CH3)C(O)-, -N(trifluoroethyl)C(O)-, -N(cyclopropyl)-C(O)-, -O-CH2-, -N(cyclopropyl)-, -N(methoxy)-, -N(trifluoroethyl)-, -N(propynyl)-, -N(propynyl)-, -N(propynyl)-, -N(allyl)-, -NHC(O)O-CH2-, piperidinyl, -O-, -Se-, -N(CH3)-SO2-, -N(cyclopropyl)-SO2-, -N(methoxy)-SO2-, -N(trifluoroethyl)-SO2-, -N(cyclopropyl)-C(=O)O-, -N(cyclopropyl)-C(=O)NH-, -OC(=O)-、

[0110] In some implementations, L 21 Selected from C 2-6 imidene group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 Alkylene, 4-6 membered heterocyclic alkyl, -O-, -Se-, -NR y -SO2-、-NR L2 -、-NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, -NR y -C(=O)-, -NH-C(=O)-, -NR y -C(=O)O-、-NR y -C(=O)NH-、-C(=O)-NR y -、-SO2-NR y -、-OC(=O)-NR y -、-OC(=O)-;

[0111] In some implementations, L 21 Selected from -NR L2 -、-N(C 3-4 cycloalkyl)-C(=O)-, -NR y -C(=O)O-、-NR y -C(=O)NH-、-NR y -SO2-;

[0112] In some implementations, L 21 Selected from -NR L2 -;

[0113] In some implementations, L 21 Selected from -OC(=O)-, -Se-, -NHC(O)O-CH2-,

[0114] In some implementations, L 21 Selected from

[0115] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-6 Alkyl, -NR y -SO2C 1-6 Alkyl, -NR y -CN, -SO2-C 3-6 cycloalkyl, -SO2-C 1-6 Alkyl, or -SO2- (4-6-membered heterocyclic alkyl), -SO2- (5-6-membered heteroaryl), wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclic alkyl, heteroaryl, or phenyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0116] In some implementations, R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-6 Alkyl, -NR y -SO2C 1-6 Alkyl, -NR y-CN, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, or phenyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0117] In some implementations, R L2 Selected from deuterium, halogens, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0118] In some implementations, R L2 Selected from C 1-4 Haloalkyl, C 3-6 cycloalkyl, wherein the alkyl group or cycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0119] In some implementations, R L2 Selected from -CF3, -CH2F, -CHF2, -CH2CF3, -CH2CHF2, -CH2CH2F, -CHFCH3, -CF2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups are optionally further oxidized by 1-5 R groups. x Replaced;

[0120] In some implementations, R L2 Selected from -CH2CF3, cyclopropyl, wherein the cyclopropyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0121] In some implementations, R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2-CN, -SO2-C 1-2 Alkyl group, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6-membered heterocycloalkyl), -SO2- (5-6-membered heteroaryl), wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0122] In some implementations, R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2 -CN, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0123] In some implementations, R L2 Selected from deuterium, -CH2-C 3-6 Cycloalkyl, -C(O)-C 3-6 Cycloalkyl, -C(O)-(5-6-membered heteroaryl), -CH2-(5-6-membered heteroaryl)-, -CH2-(4-6-membered heterocycloalkyl)-, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-2 Deuterated alkyl, C 1-3 Haloalkyl, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl, -SO2-C 1-2 Alkyl group, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6-membered heterocycloalkyl), -SO2- (5-6-membered heteroaryl), wherein the -CH2-, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, and alkynyl groups are optionally further selected by 1-4 groups selected from deuterium, CN, halogen, hydroxyl, =CH2, =CF2, =C(CH3)2, =O, C 1-2 Alkyl, C1-2 Haloalkyl, C 3-4 Substitution of cycloalkyl, 5-membered heteroaryl, and 4-6-membered heterocycloalkyl groups;

[0124] In some implementations, R L2 Selected from C 2-4 alkenyl, C 3-4 cycloalkyl, -SO2-C 3-4 cycloalkyl, C 2-4 alkynyl group, -SO2-C 1-2 Alkyl, -CH2-C 3-4 Cycloalkyl, wherein the alkenyl, cycloalkyl, alkynyl, alkyl, and -CH2- are optionally further substituted with 1-3 groups selected from halogens, CN, and hydroxyl groups;

[0125] In some implementations, R L2 Selected from -CH2CF3, -CH2CH=CH2、

[0126] In some implementations, R L2 Selected from cyclopropyl, wherein the cyclopropyl group is optionally further surrounded by 1-3 R groups. x Replaced;

[0127] In some implementations, R L2 Selected from cyclopropyl, wherein the cyclopropyl group is optionally further substituted with 1-2 groups selected from deuterium, CN, halogen, and hydroxyl;

[0128] In some implementations, R L2 Selected from cyclopropyl;

[0129] In some implementations, Selected from

[0130] In some implementations, Selected from

[0131] In some implementations, Selected from

[0132] Each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8 cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, NH is optionally further selected from 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution;

[0133] In some implementations, each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C)1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 1-4 alkylamine group, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 6 membered aryl, 5-6 membered heteroaryl, -NH(C 3-6 cycloalkyl) or -NH-O-(C 3-6 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, NH is optionally further selected from 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution;

[0134] In some implementations, each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8-membered heterocycloalkyl, 6-8-membered aryl, or 5-10-membered heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further selected from 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Substitution of deuterated alkoxy groups;

[0135] In some implementations, each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, wherein the alkyl, alkoxy, cycloalkyl or heterocyclic alkyl may optionally be further selected from 1-3 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, =CH2, =CF2, =CHF, =CH(C 1-3Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Substitution of deuterated alkoxy groups;

[0136] In some implementations, each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl;

[0137] In some implementations, each R x Each is independently selected from deuterium, halogen, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl;

[0138] In some implementations, each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl;

[0139] In some implementations, each R x Each is independently selected from deuterium, F, Cl, cyano, amino, =O, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl;

[0140] In some implementations, each Rx Each is independently selected from deuterium, F, Cl, cyano, amino, =O, -NHCOCH3, -N(CH3)2, -NH(CH3), -SF5, =CH2, =CF2, =CHF, =CH(CH3), =C(CH3)2, C 1-4 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl;

[0141] In some implementations, each R x Each is independently selected from deuterium, F, Cl, cyano, =O, -NHCOCH3, -N(CH3)2, -NH(CH3), -SF5, C 1-4 Alkyl, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 3-6 cycloalkyl;

[0142] In some implementations, each R x Each group is independently selected from cyano and =CH2;

[0143] t is an integer between 0 and 5;

[0144] In some implementations, t is an integer between 0 and 3;

[0145] In some implementations, t is selected from 0, 1, 2, and 3;

[0146] In some implementations, t is an integer from 1 to 2;

[0147] In some implementations, t is 1;

[0148] In some implementations, t is 0;

[0149] The condition is that the compound of formula (I) satisfies the following conditions:

[0150] 1) L2 is not selected from -CH2-; or

[0151] 2) When L2 is selected from key, C 1-6 Alkylene, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6For alkylene groups -O- and -NH-C(=O)-, t is not 0, and there is at least one R. C Not selected from =O or C 1-6 alkyl.

[0152] The first specific technical solution involves a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof:

[0153] Wherein, ring C is selected from a bonded carbon ring, a 3-15 membered carbon ring, or a 4-15 membered heterocycle. When ring C is selected from a bonded carbon ring, R... C Directly connected to L2;

[0154] Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -Cy2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, C 2-6 alkenyl, C 2-6 alkynyl group, -C 1-3 Alkyl-NRy-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 Cycloalkyl, 5-6 membered heteroaryl, -C(=S)NR y -C 3-8 cycloalkyl, -C(=S)NH-C 3-8 cycloalkyl, =NC 3-8 Cycloalkyl, -NH- (4-8 membered heterocycloalkyl), -NR y -(4-8 membered heterocyclic alkyl groups), C 1-6 Halogenated alkyl groups, -NH- (5-6 membered heteroaryl groups), -NR y -(5-6-membered heteroaryl), wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, C 2-6 alkenyl, C 2-6 alkynyl group, -C 1-3 Alkyl-NRy-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 Cycloalkyl, 5-6 membered heteroaryl, -C(=S)NR y -C 3-8 cycloalkyl, -C(=S)NH-C 3-8 cycloalkyl, =NC 3-8 Cycloalkyl, -NH- (4-8 membered heterocycloalkyl), -NR y -(4-8-membered heterocyclic alkyl), wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocyclic alkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from halogens, =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, C 2-6 alkenyl, C 2-6 alkynyl group, -C 1-3 Alkyl-NRy-C 3-8Cycloalkyl, 5-6 membered heteroaryl, -C(=S)NR y -C 3-8 cycloalkyl, =NC 3-8 Cycloalkyl, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0155] R y Selected from D and C 1-4 Alkyl, C 1-4 Alkoxy, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, C 3-6 cycloalkyl;

[0156] Ra and Rb are each independently selected from hydrogen, deuterium, cyano, and C. 1-6 Alkyl, C 1-6 alkoxy groups, wherein the alkyl or alkoxy group is optionally further surrounded by 1-5 R groups. x Replaced;

[0157] C y1 C y2 C y3 Each cycloalkyl group is independently selected from 3-8-membered cycloalkyl, 4-10-membered heterocycloalkyl, 5-6-heteroaryl, and 6-8-membered aryl, wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0158] L2 is selected from the bond, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR L2 -SO2-、-NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-,-N(SO2-C 3-8 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH-, -OC(=O)-, -C(=O)-NR y -、-OC(=O)-NR y -、-SO2-NR y -, wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced; in some embodiments, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)-, -N(SO2-C3-8 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH-, -OC(=O)-, -C(=O)-NR y -、-OC(=O)-NR y -、-SO2-NR y -, wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0159] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-6 Alkyl, -NR y -SO2C 1-6 Alkyl, -NR y -CN, -SO2-C 3-6 cycloalkyl, -SO2-C 1-6 Alkyl, -SO2- (4-6-membered heterocyclic alkyl), -SO2- (5-6-membered heteroaryl), wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclic alkyl, heteroaryl, or phenyl group is optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-6 Alkyl, -NR y -SO2C 1-6 Alkyl, -NR y -CN, -SO2-C 3-6cycloalkyl, -SO2-C 1-6 Alkyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, or phenyl group is optionally further reinforced with 1-5 R groups. x Replaced;

[0160] Each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8 cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, NH is optionally further selected from 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC1-3 Alkyl group substitution;

[0161] t is an integer between 0 and 5;

[0162] The condition is that the compound of formula (I) satisfies the following conditions:

[0163] 1) L2 is not selected from -CH2-; or

[0164] 2) When L2 is selected from key, C 1-6 Alkylene, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 For alkylene groups -O- and -NH-C(=O)-, t is not 0, and there is at least one R. C Not selected from =O and C 1-6 alkyl.

[0165] The second specific technical solution involves a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof:

[0166] Among them, the ring C is selected from bonds, 3-15 membered carbon rings or 4-15 membered heterocycles;

[0167] Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl)2, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further modified by 1-5 R x Replaced;

[0168] R y Selected from D and C 1-4 Alkyl, C 1-4 Alkoxy, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, C 3-6 cycloalkyl;

[0169] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8-membered heterocyclic alkyl), wherein the alkoxy, alkynyl, cycloalkyl, heterocyclic alkyl, NH2, NH are optionally further surrounded by 1-5 R groups. x Replaced;

[0170] C y1 C y2 C y3 Each cycloalkyl group is independently selected from 3-8-membered cycloalkyl, 4-10-membered heterocycloalkyl, 5-6-heteroaryl, and 6-8-membered aryl, wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0171] L2 is selected from the bond, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)- or -N(SO2-C 3-8 cycloalkyl), wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0172] In some implementations, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 Alkyl)-SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 (alkylene), wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, or -NH is optionally surrounded by 1-5 R. x Replaced;

[0173] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-6 Alkyl, -NR y -SO2C 1-6 Alkyl, -NR y -CN, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, or phenyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0174] In some implementations, R L2 Selected from deuterium, halogens, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl, wherein the alkyl, alkoxy, cycloalkyl, or heterocyclic alkyl may optionally be further surrounded by 1-5 R groups. x Replaced;

[0175] Each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C)1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8 cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, NH is optionally further selected from 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution;

[0176] t is an integer between 0 and 5;

[0177] The condition is that 1) L2 is not selected from -CH2-;

[0178] 2) When L2 is selected from key, C 1-6 Alkylene, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 For alkylene groups -O- and -NH-C(=O)-, t is not 0, and there is at least one R. C Not selected from =O and C 1-6 alkyl.

[0179] The specific third technical solution involves a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof:

[0180] Among them, the ring C is selected from bonds, 3-15 membered carbon rings or 4-15 membered heterocycles;

[0181] Each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl groups, wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, or NH2 may optionally be further radicalized by 1-5 R groups. x Replaced;

[0182] C y1 C y2C y3 Each cycloalkyl group is independently selected from 3-8-membered cycloalkyl, 4-10-membered heterocycloalkyl, 5-6-heteroaryl, and 6-8-membered aryl, wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0183] L2 is selected from the bond, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 Alkyl)-SO2-, wherein the alkylene, alkenylene, ynylene, cycloalkyl, or heterocycloalkyl group is optionally surrounded by 1-5 R groups. x Replaced;

[0184] R L2 Selected from deuterium, halogens, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl, wherein the alkyl, alkoxy, cycloalkyl, or heterocyclic alkyl may optionally be further surrounded by 1-5 R groups. x Replaced;

[0185] Each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8-membered heterocycloalkyl, 6-8-membered aryl, or 5-10-membered heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further selected from 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Substitution of deuterated alkoxy groups;

[0186] t is an integer between 0 and 5;

[0187] The condition is that 1) L2 is not selected from -CH2-;

[0188] 2) When L2 is selected from key, C 1-6 Alkylene, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 For alkylene groups -O- and -NH-C(=O)-, t is not 0, and there is at least one R. C Not selected from =O and C 1-6 alkyl.

[0189] The fourth specific technical solution involves a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof:

[0190] Among them, ring C is selected from 3-15 membered carbon rings or 4-15 membered heterocycles;

[0191] Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6Alkyl)2, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further modified by 1-5 R x Replaced;

[0192] R y Selected from D and C 1-4 Alkyl, C 1-4 Alkoxy, deuterated C 1-4 Alkyl, Halogenated C 1-4 Alkyl, C 3-6 cycloalkyl;

[0193] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, each R CEach is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), 4-8 membered heterocyclic alkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, C 1-6 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy groups, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -C(=O)-C 3-8Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocycloalkyl), -C(=O)NH- (4-8 membered heterocycloalkyl), -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0194] C y1 C y2 C y3 Each cycloalkyl group is independently selected from 3-8-membered cycloalkyl, 4-10-membered heterocycloalkyl, 5-6-heteroaryl, and 6-8-membered aryl, wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0195] L2 is selected from the bond, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR y -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3Alkyl), wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced; in some embodiments, L2 is selected from key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, wherein the alkylene, alkenylene, ynylene, cycloalkyl, or heterocycloalkyl group is optionally prefixed with 1-5 R groups. x Replaced; in some implementations, L2 is selected from the key, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-6 alkylene-, wherein the alkylene, alkenylene, or yntylide is optionally surrounded by 1-5 R- groups. x Replaced;

[0196] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-6 Alkyl, -NR y -SO2C 1-6 Alkyl, -NR y -CN, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, or phenyl group is optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R L2 Selected from deuterium, halogens, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl, wherein the alkyl, alkoxy, cycloalkyl, or heterocyclic alkyl may optionally be further surrounded by 1-5 R groups. x Replaced;

[0197] Each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =CH(C) 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =CF(C) 1-3 Halogenated alkyl), =C(C 1-3 Alkyl)2、=C(C 1-3 Alkyl)(C 1-3 Halogenated alkyl), =C 4-6 Cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8-membered heterocycloalkyl, 6-8-membered aryl, or 5-10-membered heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further selected from 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Substitution of deuterated alkoxy groups;

[0198] t is an integer between 0 and 5;

[0199] The condition is that 1) L2 is not selected from -CH2-;

[0200] 2) When L2 is selected from key, C 1-6 Alkylene, -C 1-6 Alkylene -C(=O)-, -OC 1-6 alkylene-, -C 1-6 For alkylene groups -O- and -NH-C(=O)-, t is not 0, and there is at least one R. C Not selected from =O or C 1-6 alkyl.

[0201] The fifth specific technical solution relates to a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein general formula (I) is further shown as general formula (II), formula (III), formula (VI), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), or formula (X):

[0202] Selected from Preferred Selected from

[0203] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), -C(=O)-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 cycloalkyl, 5-6 membered heteroaryl, -C(=S)NH-C 3-8 cycloalkyl, =NC 3-8 Cycloalkyl, -NH- (4-8 membered heterocycloalkyl), -NR y -(4-8 membered heterocyclic alkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6 heteroaryl groups), -NH-C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced; in some implementations, R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0204] Ra and Rb are each independently selected from hydrogen, cyano, and C. 1-4 Alkyl, C 1-4 alkoxy groups, wherein the alkyl or alkoxy group is optionally further surrounded by 1-5 R groups. x Replaced;

[0205] L 21 Selected from C 2-6 imidene group, -C 1-6 Alkylene -C(=O)-, -OC 1-6Alkylene, 4-6 membered heterocyclic alkyl, -O-, -Se-, -NR y -SO2-、-NR L2 -、-NH-C(=O)OC 1-6 Alkylene, 3-6 membered cycloalkyl, -NR y -C(=O)-, -NH-C(=O)-, -NR y -C(=O)O-、-NR y -C(=O)NH-、-C(=O)-NR y -、-SO2-NR y -、-OC(=O)-NR y -、-OC(=O)-;

[0206] t is 0, 1, 2, 3, or 4;

[0207] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0208] The sixth specific technical solution involves a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein general formula (I) is further shown as general formula (II), formula (III), formula (VI), formula (V), formula (VI), formula (VII), formula (VIII), and formula (IX):

[0209] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), -C(=O)-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 cycloalkyl, 5-6 membered heteroaryl, -C(=S)NH-C 3-8 cycloalkyl, =NC 3-8 Cycloalkyl, -NH- (4-8 membered heterocycloalkyl), -NR y -(4-8-membered heterocyclic alkyl), wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocyclic alkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced; in some implementations, R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0210] Ra and Rb are each independently selected from hydrogen, cyano, and C. 1-4 Alkyl, C 1-4 alkoxy groups, wherein the alkyl or alkoxy group is optionally further surrounded by 1-5 R groups. x Replaced;

[0211] L 21 Selected from C 2-6 imidene group, -C 1-6 Alkylene -C(=O)-, -OC 1-6 Alkylene, 4-6 membered heterocyclic alkyl, -O-, -Se-, -NR y -SO2-、-NR L2 -、-NH-C(=O)OC 1-6Alkylene, 3-6 membered cycloalkyl, -NR y -C(=O)-, -NH-C(=O)-, -NR y -C(=O)O-、-NR y -C(=O)NH-、-C(=O)-NR y -、-SO2-NR y -、-OC(=O)-NR y -、-OC(=O)-;

[0212] t is 0, 1, 2, 3, or 4;

[0213] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0214] The specific seventh technical solution relates to a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein general formula (I) is further shown as general formula (II), formula (III), formula (VI), formula (V), formula (VI), formula (VII), and formula (VIII):

[0215] R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0216] t is 0, 1, 2, 3, or 4;

[0217] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0218] The specific eighth technical solution involves a compound of general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, wherein general formula (I) is further shown as general formula (II), formula (III), formula (VI), formula (V) and formula (VI):

[0219] R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0220] t is 0, 1, 2, 3, or 4;

[0221] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0222] The specific ninth technical solution relates to a compound of general formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein general formula (I) is further shown as in general formula (II), formula (III), formula (VI), and formula (V):

[0223] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, and NH are optionally further modified by 1-5 R groups. x Replaced;

[0224] In some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 cycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0225] t is 0, 1, 2, 3, or 4;

[0226] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0227] Specifically, in the tenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0228] The ring C is selected from bonds, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 7-11 bicyclic heterocyclic group, 7-12 tricyclic heterocyclic group, 5-6 membered heteroaryl, and 6-8 membered aryl;

[0229] Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl groups, -NH- (5-6 membered heteroaryl groups), -NR y -(5-6-membered heteroaryl), wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl is optionally further surrounded by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 cycloalkyl, C 2-6 Alkenyl, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl, optionally further surrounded by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 1-6Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R xReplaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6 membered heteroaryl), -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 Cycloalkyl, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0230] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocyclic alkyl), 4-6 membered heterocyclic alkyl, -SO2NH-C 3-6 Cycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3-OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 cycloalkyl, -C(=S)NH-C 3-8 Cycloalkyl, -NH- (4-6 membered heterocycloalkyl), -NR y -(4-6 membered heterocyclic alkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6-membered heteroaryl), wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0231] In some implementations, R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocyclic alkyl), 4-6 membered heterocyclic alkyl, -SO2NH-C 3-6 Cycloalkyl, 3-8 membered cycloalkyl, -C1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0232] L2 is selected from the bond, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR L2 -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)-, -N(SO2-C 3-8 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH- or -OC(=O)-, wherein the alkylene, alkenylene, ynylene, heteroaryl, -NH, or cycloalkyl group is optionally surrounded by 1-5 R groups. x Replaced;

[0233] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2 -CN, -SO2-C 1-2 Alkyl group, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6-membered heterocycloalkyl), -SO2- (5-6-membered heteroaryl), wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl group is optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2 -CN, -SO2-C 1-2 Alkyl groups, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2 -CN, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0234] Each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl, aryl or heteroaryl, NH optionally further selected from 1-3 radicals selected from deuterium, halogen, hydroxyl, cyano, amino, =O, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution;

[0235] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-6 cycloalkyl;

[0236] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0237] Specifically, in the eleventh technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0238] The ring C is selected from bonds, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 7-11 bicyclic heterocyclic group, 7-12 tricyclic heterocyclic group, 5-6 membered heteroaryl, and 6-8 membered aryl;

[0239] Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0240] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocyclic alkyl), 4-6 membered heterocyclic alkyl, -SO2NH-C 3-6 Cycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R groups. x Replaced;

[0241] L2 is selected from the bond, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR L2 -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)-, -N(SO2-C 3-8 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH- or -OC(=O)-, wherein the alkylene, alkenylene, ynylene, heteroaryl, -NH, or cycloalkyl group is optionally surrounded by 1-5 R groups. x Replaced;

[0242] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2 -CN, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0243] Each R x Each is independently selected from deuterium, halogen, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8 cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl, aryl or heteroaryl, NH optionally further selected from 1-3 radicals selected from deuterium, halogen, hydroxyl, cyano, amino, =O, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution;

[0244] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-6 cycloalkyl;

[0245] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0246] Specifically, in the twelfth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0247] The ring C is selected from cyclic carbon, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 7-11 bicyclic heterocyclic group, 7-11 tricyclic heterocyclic group, 5-6 membered heteroaryl, and 6-8 membered aryl.

[0248] In some embodiments, the cyclic C is selected from bonds, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 5-6 membered heteroaryl, and 6-8 membered aryl;

[0249] Each R CEach is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further modified by 1-5 R x Replaced;

[0250] In some implementations, each R CEach is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8-membered heterocyclic alkyl), wherein the alkoxy, alkynyl, cycloalkyl, heterocyclic alkyl, NH2, NH are optionally further surrounded by 1-5 R groups. x Replaced;

[0251] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocyclic alkyl), 4-6 membered heterocyclic alkyl, -SO2NH-C 3-6 Cycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, and NH are optionally further modified by 1-5 R groups. x Replaced;

[0252] In some implementation schemes, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0253] L2 is selected from the bond, C1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR L2 -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl)- or -N(SO2-C 3-8 cycloalkyl), wherein the alkylene, alkenylene, ynylene, heteroaryl, -NH, or cycloalkyl group is optionally surrounded by 1-5 R groups. x Replaced; in some implementations, L2 is selected from the key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-5 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 Alkyl)-SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 (alkylene), wherein the alkylene, alkenylene, ynylene, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0254] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2 -CN, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0255] In some implementation schemes, R L2 Selected from deuterium, halogens, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0256] Each R x Each is independently selected from deuterium, halogen, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8 cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl, aryl or heteroaryl, NH optionally further selected from 1-3 radicals selected from deuterium, halogen, hydroxyl, cyano, amino, =O, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution;

[0257] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-6 cycloalkyl;

[0258] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0259] Specifically, in the thirteenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0260] The ring C is selected from bonds, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 5-6 membered heteroaryl, and 6-8 membered aryl;

[0261] Each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl groups, wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, or NH2 may optionally be further radicalized by 1-5 R groups. x Replaced;

[0262] R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1-C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0263] L2 is selected from the bond, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-5 membered heterocycloalkyl, -O-, -Se-, -N(C) 1-3 Alkyl)-C(=O)-, -N(C 1-3 alkyl)-SO2-, wherein the alkylene, alkenylene, or yntylide is optionally surrounded by 1-5 R... x Replaced;

[0264] R L2 Selected from deuterium, halogens, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0265] Each R x Each is independently selected from deuterium, halogen, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-8Cycloalkyl, 4-8 membered heterocyclic alkyl, wherein the alkyl, alkoxy, cycloalkyl or heterocyclic alkyl may optionally be further selected from 1-3 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =O, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Substitution of deuterated alkoxy groups;

[0266] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0267] Specifically, in the fourteenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0268] The ring C is selected from cyclic carbon, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 7-11 bicyclic heterocyclic group, 7-11 tricyclic heterocyclic group, 5-6 membered heteroaryl, and 6-8 membered aryl.

[0269] In some embodiments, the ring C is selected from 3-6-membered cycloalkyl, 4-8-membered heterocycloalkyl, 5-6-membered heteroaryl, and 6-8-membered aryl;

[0270] Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1-C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, wherein the alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further modified by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups.x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, C 1-6 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 cycloalkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0271] R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocyclic alkyl), 4-6 membered heterocyclic alkyl, -SO2NH-C 3-6 Cycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, and NH are optionally further modified by 1-5 R groups. x Replaced; in some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -Cy1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0272] L2 is selected from the bond, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-、-N(C 1-3 Alkyl groups -SO2-, -NH-, -NR L2 -SO2-, -N = 4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-6 Cycloalkyl-(5-6-membered heteroaryl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 Alkyl), wherein the alkylene, alkenylene, ynylene, heteroaryl, or -NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0273] In some implementations, L2 is selected from key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)OC 1-4 Alkylene, 3-5 membered cycloalkyl, 4-5 membered heterocycloalkyl, wherein the alkylene, alkenylene, or ynylene group is optionally surrounded by 1-5 R groups. x Replaced; in some implementations, L2 is selected from the key, C 1-4 Alkylene, C 2-4 imidene group, C 2-4 Ethyne group, -C 1-4 Alkylene -C(=O)-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR L2-, -NH-C(=O)-, -NH-C(=O)OC 1-4 alkylene-, wherein the alkylene, alkenylene, or yntylide is optionally surrounded by 1-5 R- groups. x Replaced;

[0274] R L2 Selected from deuterium, halogens, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 Alkyl, -NR L2 -SO2C 1-2 Alkyl, -NR L2 -CN, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, or alkynyl group is optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R L2 Selected from deuterium, halogens, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl, or heterocycloalkyl group is optionally further surrounded by 1-5 R groups. x Replaced;

[0275] Each R x Each is independently selected from deuterium, halogen, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6Deuterated alkoxy, C 3-8 Cycloalkyl, 4-8-membered heterocycloalkyl, 6-8-membered aryl, or 5-10-membered heteroaryl, wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl, aryl or heteroaryl, NH is optionally further selected from 1-3 elements selected from deuterium, halogen, hydroxyl, cyano, amino, =O, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution;

[0276] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-6 cycloalkyl;

[0277] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0278] Specifically, in the fifteenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0279] The ring C is selected from the following groups: cyclobutenyl,

[0280] In some embodiments, the cyclic C is selected from the following groups: cyclobutenyl,

[0281] In some embodiments, the cyclic C is selected from the following groups: cyclobutenyl, In some embodiments, the cyclic C is selected from the following groups: cyclobutenyl, In some embodiments, the cyclic C is selected from the following groups:

[0282] Each R CEach is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -SO2NH-C 3-6 cycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, C 2-4 alkenyl, C2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4 Haloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl is optionally further surrounded by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -SO2NH-C 3-6 cycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -N=S(=O)(C 1-6Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, C 2-4 Alkenyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl, optionally further radicalized by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -SO2NH-C 3-6 cycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NRy -C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -SO2NH-C 3-6cycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NH- (5-6-membered heteroaryl), wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further surrounded by 1-5 R x Replaced;

[0283] R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-6 cycloalkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-6 cycloalkyl, -C 2-4 alkenyl-C 3-6 Cycloalkanes, -CH2-NRy-C 3-6 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-6 cycloalkyl, =NC 3-6 cycloalkyl, -CH2-NH-C 3-6 cycloalkyl, -C(=S)NH-C 3-6 Cycloalkyl, -NH- (4-6 membered heterocycloalkyl), -NR y -(4-6 membered heterocyclic alkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6 heteroaryl groups), -C(=O)NR y -C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH, CH2 optionally are further surrounded by 1-5 R x Replaced, or R C1 Selected from 1-2 of the following: =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 3-8 membered cycloalkyl groups substituted with a haloalkyl group;

[0284] In some implementations, R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-6 cycloalkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-6 cycloalkyl, -C 2-4 alkenyl-C 3-6 Cycloalkanes, -CH2-NRy-C 3-6 Cycloalkyl, -C(=O)NH-(5-6-membered heteroaryl), 5-6-membered heteroaryl, -C(=O)-C 3-6 cycloalkyl, =NC 3-6 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, or NH group is optionally further surrounded by 1-5 R groups. x Replaced, or R C1 Selected from 1-2 of the following: =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 3-8 membered cycloalkyl groups substituted with a haloalkyl group;

[0285] In some implementations, R C1 Selected from -OCHF2, -OCF3, -SCF3, -SCF3, -NHSO2NH2, -S(=O)(=NH)-CH3, -N=S(=O)(CH3)2, -P(=O)(CH3)2, -C(=O)NH-CH2-CN, -C(=O)NH-CH(CH3)-CF3, -S(=O)2-NH-C(=O)O-CH3, -C(=O)NH-CN,

[0286] In some implementations, R C1 Selected from -OCHF2, -OCF3, -SCF3, -SCF3, -NHSO2NH2, -S(=O)(=NH)-CH3, -N=S(=O)(CH3)2, -P(=O)(CH3)2, -C(=O)NH-CH2-CN, -C(=O)NH-CH(CH3)-CF3, -S(=O)2-NH-C(=O)O-CH3, -C(=O)NH-CN,

[0287] L2 is selected from the bond, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 (ynyl group)-, -NR y C(O)-、-NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y -SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-4 Cycloalkyl-(5-6-membered heteroaryl)-, -N(5-6-membered heteroaryl)-, -N(phenyl)-, -N(-NR)- y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-、-N(C 3-6 Cycloalkyl)-, -N(4-6 membered heterocycloalkyl)-, -N(SO2-C 3-6 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH-, -OC(=O)- or -N(SO2C) 1-6 alkyl)-, -N(C 2-4 -Halogenated alkenyl), -N(SO2-4-membered heterocyclic alkyl), -N(SO2-5-membered heteroaryl), -N(C 1-4 Alkyl), wherein the alkylene, alkenylene, alkynyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, or -NH is optionally surrounded by 1-5 R. x Replaced; in some embodiments, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 (ynyl group)-, -NR y C(O)-、-NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y-SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 alkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-4 Cycloalkyl-(5-6-membered heteroaryl)-, -N(5-6-membered heteroaryl)-, -N(phenyl)-, -N(-NR)- y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-、-N(C 3-6 Cycloalkyl)-, -N(4-6 membered heterocycloalkyl)-, -N(SO2-C 3-6 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH-, -OC(=O)- or -N(SO2C) 1-6 Alkyl), wherein the alkylene, alkenylene, alkenylene, alkyne, cycloalkyl, heterocycloalkyl, or heteroaryl-NH group is optionally surrounded by 1-5 R groups. x Replaced; in some embodiments, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 (ynyl group)-, -NR y C(O)-、-NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, aziridine, -O-, -Se-, -N(C) 1-2Alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y -SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 alkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-4 Cycloalkyl-(5-6-membered heteroaryl)-, -N(5-6-membered heteroaryl)-, -N(phenyl)-, -N(-NR)- y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-、-N(C 3-6 -cycloalkyl), -N (4-6 membered heterocycloalkyl), or -N (SO2-C) 3-6 cycloalkyl)-, -NR y -C(=O)O-、-NR y -C(=O)NH- or -OC(=O)-, wherein the alkylene, alkenylene, ynylene, alkenyl, ynylene, cycloalkyl, heterocycloalkyl, or heteroaryl-NH group is optionally surrounded by 1-5 R groups. x Replaced;

[0288] L 21 Selected from -OC(=O)-, -Se-, -NHC(O)O-CH2-, In some implementations, L 21 Selected from -OC(=O)-, -Se-, -NHC(O)O-CH2-, In some implementations, L 21 Selected from -OC(=O)-, -Se-, -NHC(O)O-CH2-,

[0289] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C1 -2 Alkyl, C 3-6 cycloalkyl;

[0290] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0291] Specifically, in the sixteenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0292] The ring C is selected from the following groups: cyclobutenyl,

[0293] In some embodiments, the cyclic C is selected from the following groups:

[0294] Each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -SO2NH-C 3-6 cycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -N=S(=O)(C 1-6 Alkyl)2, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further modified by 1-5 R x Replaced;

[0295] In some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, -NHSO2NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3Alkyl-(4-8-membered heterocyclic alkyl), wherein the alkoxy, alkynyl, cycloalkyl, heterocyclic alkyl, NH2, NH are optionally further surrounded by 1-5 R groups. x Replaced;

[0296] R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-6 cycloalkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, and NH groups are optionally further surrounded by 1-5 R groups. x Replaced, or R C1 Selected from 1-2 of the following: =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-33-8 membered cycloalkyl groups substituted with a haloalkyl group; in some embodiments, R C1 Selected from =S, =NH, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0297] L2 is selected from the bond, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 (ynyl group)-, -NR y C(O)-、-NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y -SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C4-6 cycloalkyl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 alkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-4 Cycloalkyl-(5-6-membered heteroaryl)-, -N(5-6-membered heteroaryl)-, -N(phenyl)-, -N(-NR)- y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-、-N(C 3-6 -cycloalkyl), -N (4-6 membered heterocycloalkyl), or -N (SO2-C) 3-6 cycloalkyl), wherein the alkylene, alkenylene, alkenylene, alkyne, cycloalkyl, heterocycloalkyl, or heteroaryl-NH group is optionally surrounded by 1-5 R groups. x Replaced; in some embodiments, L2 is selected from key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 Alkyl)-SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 (alkylene), wherein the alkylene, alkenylene, ynylene, cycloalkyl, heterocycloalkyl, or -NH is optionally surrounded by 1-5 R. x Replaced;

[0298] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-6 cycloalkyl;

[0299] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0300] Specifically, in the seventeenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0301] Ring C is selected from 1-3 of the elements selected from R. C The following groups are substituted:

[0302] Each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, -NHSO2NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl groups, wherein the alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, or NH2 may optionally be further radicalized by 1-5 R groups. x Replaced;

[0303] R C1Selected from =S, =NH, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0304] L2 is selected from the bond, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 (alkyl)-SO2-;

[0305] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0306] Specifically, in the eighteenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0307] The ring C is selected from the following groups: cyclobutenyl,

[0308] In some implementations, ring C is selected from 1-3 rings selected from R. C The following groups are substituted:

[0309] Each R C Each is independently selected from =O, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -SO2NH-C 3-6 cycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -N=S(=O)(C 1-6 Alkyl)2, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further modified by 1-5 R x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, -NHSO2NH2, C 1-4 Alkyl, C1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, -NHSO2NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-4 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, each R C Each is independently selected from =O, =S, =Se, =NH, -SCF3, C 1-4 Alkyl, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, -OC 3-6Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl, -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0310] R C1 Selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-6 cycloalkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -N=S(=O)(C 1-6 alkyl)2 or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, and NH groups are optionally further surrounded by 1-5 R groups. x Replaced, or R C1 Selected from 1-2 of the following: =CH2, =CF2, =CHF, =CH(C) 1-3Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 3-8 membered cycloalkyl groups substituted with a haloalkyl group;

[0311] In some implementation schemes, R C1 Selected from =S, =NH, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -O- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R C1 Selected from =S, =NH, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced; in some implementations, R C1Selected from =S, =NH, -SCF3, C 2-4 alkynyl-cyano, C 1-6 Haloalkoxy, =CH2, =CF2, -OC 3-6 Cycloalkyl, -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 Cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl or -C y1 -C y2 -C y3 The alkoxy, alkynyl, cycloalkyl, or heterocycloalkyl groups are optionally further surrounded by 1-5 R groups. x Replaced;

[0312] L2 is selected from the bond, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 (ynyl group)-, -NR y C(O)-、-NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine, aziridine, -O-, -Se-, -N(C) 1-2 Alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y -SO2-, -NH-, -N=4-8 membered heterocyclic alkyl-, -N(C 1-3 Alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 ynyl group)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(C 2-6 alkenyl)-, -N(C 2-6 ynyl group)-, -N(C 1-3 alkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 Heterocyclic alkyl)-, -N(CO-(5-6 membered heteroaryl))-, -N(C 3-4 Cycloalkyl-(5-6-membered heteroaryl)-, -N(5-6-membered heteroaryl)-, -N(phenyl)-, -N(-NR)-y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-、-N(C 3-6 cycloalkyl)-, -N(4-6 membered heterocycloalkyl)-, wherein the alkylene, alkenylene, ynylene, alkenyl, cycloalkyl, heterocycloalkyl, heteroaryl-NH is optionally surrounded by 1-5 R x Replaced; in some implementations, L2 is selected from the key, C 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene, cyclopropyl, cyclobutyl, oxetyl, aziridine; in some embodiments, L2 is selected from the C-bonded group. 2-4 alkenyl, -C(O)-, -C 1-2 Alkylene-C(O)-, -OC 1-2 Alkylene-, -N(C) 3-6 cycloalkyl)-, -N(C 1-4 (halogenated alkyl)-, -NHC(O)-, -NHC(O)OC 1-2 Alkylene;

[0313] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-6 cycloalkyl;

[0314] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0315] Specifically, in the nineteenth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0316] Selected from In some implementation schemes, Selected from In some implementation schemes, Selected from

[0317] Ring C is selected from 7-11 bicyclic heterocyclic groups and 5-6 heteroaryl groups;

[0318] L 21 Selected from -NR L2 -、-N(C 3-4 cycloalkyl)-C(=O)-, -NR y -C(=O)O-、-NR y -C(=O)NH-、-NR y -SO2-; In some implementations, L 21 Selected from -NR L2 -;

[0319] R L2 Selected from deuterium, -CH2-C 3-6 Cycloalkyl, -C(O)-C 3-6 Cycloalkyl, -C(O)-(5-6-membered heteroaryl), -CH2-(5-6-membered heteroaryl)-, -CH2-(4-6-membered heterocycloalkyl)-, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-2 Deuterated alkyl, C 1-3 Haloalkyl, C 1-4 Halogenated alkoxy groups, C 1-4 Deuterated alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl, -SO2-C 1-2 Alkyl group, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6-membered heterocycloalkyl), -SO2- (5-6-membered heteroaryl), wherein the -CH2-, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, and alkynyl groups are optionally further selected by 1-4 groups selected from deuterium, CN, halogen, hydroxyl, =CH2, =CF2, =C(CH3)2, =O, C 1-2 Alkyl, C 1-2 Haloalkyl, C 3-4 Substitution of cycloalkyl, 5-membered heteroaryl, and 4-6-membered heterocycloalkyl groups;

[0320] R C Selected from CN, C 1-4 Alkyl, C 1-4 Alkoxy, -C 1-4 Haloalkoxy group, -C(=O)NH-C 3-6 cycloalkyl, -NHC(=O)-C 3-6 Cycloalkyl, -CONH-(5-6 heteroaryl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, halogen, 5-6 membered heteroaryl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-4 Deuterated alkyl, C 1-4Haloalkyl, -O- (3-6 membered cycloalkyl), -N=S (=O) (C 1-3 Alkyl)2, -NHSO2- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -C(=O)NR y -C 3-6 cycloalkyl, -SO2-C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6 membered heteroaryl), -C(=O)-(4-6 membered heterocyclic alkyl), -NH-C 3-6 cycloalkyl, -SO2NH-C 3-6 Cycloalkyl, -C(=O)-(5-6-membered heteroaryl), -NH-(5-6-membered heteroaryl), -C(=O)-C 3-6 Cycloalkyl, -O-(5-6-membered heteroaryl), =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, wherein the alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, or alkynyl group is optionally further selected from 1-4 C 1-2 Alkyl, C 1-2 Haloalkyl, =O, halogen, 3-4 membered cycloalkyl, C 1-2 Deuterated alkyl, C 1-2 Alkoxy, C 1-2 Substitution of alkyl halogens, =CH2, =CF2, =C(CH3)2 groups;

[0321] R C1 Selected from -C 1-2 Haloalkoxy, -O- (3-4 membered cycloalkyl), -CONH- (3-6 cycloalkyl), -CONH- (5-6 heteroaryl), -NHC(=O)-C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -N=S(=O)(C 1-3 Alkyl)2, -NHSO2- (4-6 membered heterocyclic alkyl), -C(=O)- (4-6 membered heterocyclic alkyl), -C(=O)NR y -C 3-6 cycloalkyl, -SO2-C 3-6 cycloalkyl, -C 1-3 Alkyl-(5-6 membered heteroaryl), -C(=O)-(4-6 membered heterocyclic alkyl), -NH-C 3-6 cycloalkyl, -SO2NH-C 3-6 Cycloalkyl, -C(=O)-(5-6-membered heteroaryl), -NH-(5-6-membered heteroaryl), -C(=O)-C 3-6Cycloalkyl, -O- (5-6-membered heteroaryl), wherein the cycloalkyl, heterocycloalkyl, or heteroaryl group is optionally further selected from 1-3 elements selected from deuterium, CN, halogen, hydroxyl, or C. 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Substitution with deuterated alkyl groups, =CH2, =CF2, =C(CH3)2, =(4-6 membered heterocyclic alkyl) groups;

[0322] R y Selected from D and C 1-2 Alkyl, C 1-2 Alkoxy, deuterated C 1-2 Alkyl, Halogenated C 1-2 Alkyl, C 3-4 cycloalkyl; in some embodiments, R y Selected from C 1-2 Alkyl, cyclopropyl;

[0323] t is selected from 0, 1, 2, and 3;

[0324] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0325] Specifically, in the twentieth technical solution, the compound shown in the aforementioned general formula, its stereoisomers, or its pharmaceutically acceptable salts, wherein...

[0326] The ring C is selected from 5-10-membered heteroaryl groups; in some embodiments, the ring C is selected from 5-6-membered heteroaryl groups; in some embodiments, the ring C is selected from the following groups:

[0327] R C Selected from C 1-4 Alkyl, CN, C 1-4 Halogenated alkyl, 3-6 membered cycloalkyl, halogen, C 2-4 alkynyl group, C 2-4 alkenyl, C 1-4 Alkoxy, 5-6 membered heteroaryl, C 1-4 Deuterated alkyl or 5-6 membered heterocyclic alkyl, wherein the cycloalkyl, heteroaryl, or heterocyclic alkyl group is optionally further selected from 1-3 elements selected from =O, deuterium, CN, halogen, hydroxyl, C. 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Substitution of deuterated alkyl groups;

[0328] L 21 Selected from -NR L2 -; In some implementations, L 21 Selected from

[0329] R L2 Selected from C 2-4 alkenyl, C 3-4 cycloalkyl, -SO2-C 3-4 cycloalkyl, C 2-4 alkynyl group, -SO2-C 1-2 Alkyl, -CH2-C 3-4 Cycloalkyl, wherein the alkenyl, cycloalkyl, alkynyl, alkyl, and -CH2- are optionally further substituted with 1-3 groups selected from halogens, CN, and hydroxyl groups;

[0330] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0331] Specifically, in the twenty-first technical solution, the compounds shown in the aforementioned general formulas (IV) and (IV-1), their stereoisomers, or pharmaceutically acceptable salts thereof, wherein...

[0332] R C1 Selected from -C 1-2 The cycloalkoxy group, -O- (3-4 membered cycloalkyl), -CONH- (3-6 cycloalkyl), -CONH- (5-6 heteroaryl), wherein the cycloalkyl or heteroaryl group is optionally further selected from 1-3 elements selected from deuterium, CN, halogen, hydroxyl, C 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Substitution with deuterated alkyl groups, =CH2, =CF2, =C(CH3)2 groups; in some embodiments, R C1 Selected from -OCHF2, -OCF3,

[0333] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0334] Specifically, in the twenty-second technical solution, the compounds shown in the aforementioned general formulas (II), (IX), and (IX-1), their stereoisomers, or pharmaceutically acceptable salts thereof, wherein...

[0335] R L2 Selected from cyclopropyl, wherein the cyclopropyl group is optionally further substituted with 1-2 groups selected from deuterium, CN, halogen, and hydroxyl;

[0336] Cyclic C is selected from 5-6 membered heteroaryl groups; in some embodiments, Selected from

[0337] R C Selected from CN, C 1-2 Alkyl, C 1-2 Alkoxy, C 1-2Halogenated alkyl groups, halogens, 3-4 membered cycloalkyl groups, C 1-2 Deuterated alkyl, C 2-3 alkenyl, C 2-3 Alkyne group, 5-6 heteroaryl group, wherein the cycloalkyl group or heteroaryl group is optionally further selected from 1-3 groups selected from deuterium, CN, halogen, hydroxyl, C 1-2 Alkyl, C 1-2 Alkoxy, C 1-2 Haloalkyl, C 1-2 Deuterated alkyl groups are substituted; in some embodiments, R C Selected from -CH3, -CHF2, -CH2F, -CF3, -F, -CD3, and cyclopropyl;

[0338] t is selected from 0, 1, 2, and 3;

[0339] The definitions of other functional groups are consistent with any of the technical solutions mentioned above.

[0340] More specifically, the compounds of the present invention, their stereoisomers or pharmaceutically acceptable salts, are selected from, but not limited to, the structures listed in Tables 1 and 2 below:

[0341] Table 1

[0342] Table 2

[0343] The present invention further provides a pharmaceutical composition comprising the compound as described above, its stereoisomer or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and / or excipients.

[0344] Furthermore, the pharmaceutical composition or pharmaceutical preparation of the present invention contains 1-1500 mg of the compound described in any of the preceding embodiments, its stereoisomer or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier and / or excipient.

[0345] In some embodiments of the present invention, the above-described pharmaceutical compositions can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. The carriers refer to carriers conventional in the pharmaceutical field, such as: diluents like water; binders like cellulose derivatives, gelatin, polyvinylpyrrolidone, etc.; fillers like starch, etc.; disintegrants like calcium carbonate, sodium bicarbonate, etc.; lubricants like calcium stearate or magnesium stearate, etc. Additionally, other excipients such as sweeteners, flavoring agents, or coloring agents may be added to the composition.

[0346] In some embodiments of the invention, the pharmaceutical composition may be administered in any of the following ways: orally, by spray inhalation, rectal administration, nasal administration, buccal administration, topical administration, or parenteral administration such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal, or intracranial injection or infusion, or via an external implantation device. Oral administration is preferred.

[0347] When taken orally, the compounds of this application can be formulated into any orally acceptable dosage form, including but not limited to tablets, capsules, aqueous solutions or aqueous suspensions.

[0348] The present invention further provides the use of the compounds described above, their stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof in the preparation of medicaments for the treatment / prevention of VAV1-mediated diseases.

[0349] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of the aforementioned compound or its stereoisomers, a pharmaceutically acceptable salt, or a pharmaceutical composition, said therapeutically effective amount being 1-1500 mg, said disease being selected from autoimmune diseases, preferably rheumatoid arthritis, multiple sclerosis, and inflammatory gastroenteritis.

[0350] The present invention further provides a method for treating a disease in a mammal, comprising administering to the mammal a therapeutically effective dose of any of the indicated compounds, their stereoisomers, or pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof, or a pharmaceutical composition thereof. The disease is selected from autoimmune diseases, preferably rheumatoid arthritis, multiple sclerosis, inflammatory gastroenteritis, etc., and the therapeutically effective dose is preferably 1-1500 mg. In some embodiments, the mammals described in the present invention include humans.

[0351] The term "effective amount" or "therapeutic effective amount" as used in this application means that administering a sufficient amount of the compound disclosed in this application will alleviate, to some extent, one or more symptoms of the disease or condition being treated. In some embodiments, the result is a reduction and / or mitigation of the signs, symptoms, or causes of the disease, or any other desired alteration of the biological system. For example, an "effective amount" for therapeutic use is the amount of the compound disclosed in this application required to provide a clinically significant reduction in disease symptoms. Examples of therapeutically effective doses include, but are not limited to, 1-1500 mg, 1-1400 mg, 1-1300 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 1-500 mg, 1-400 mg, 1-300 mg, 1-250 mg, 1-200 mg, 1-150 mg, 1-125 mg, 1-100 mg, 1-80 mg, 1-60 mg, 1-50 mg, 1-40 mg, 1-25 mg, 1- 20mg, 5-1500mg, 5-1000mg, 5-900mg, 5-800mg, 5-700mg, 5-600mg, 5-500mg, 5-400mg, 5-300mg, 5-250mg, 5-200mg, 5 -150mg, 5-125mg, 5-100mg, 5-90mg, 5-70mg, 5-80mg, 5-60mg, 5-50mg, 5-40mg, 5-30mg, 5-25mg, 5-20mg, 10-1500mg, 10-1000mg, 10-900mg, 10-800mg, 10-700mg, 10-600mg, 10-500mg, 10-450mg, 10-400mg, 10-300mg, 10-250mg, 10-20 0mg, 10-150mg, 10-125mg, 10-100mg, 10-90mg, 10-80mg, 10-70mg, 10-60mg, 10-50mg, 10-40mg, 10-30mg, 10-20mg; 2 0-1500mg, 20-1000mg, 20-900mg, 20-800mg, 20-700mg, 20-600mg, 20-500mg, 20-400mg, 20-350mg, 20-300mg, 20-25 0mg, 20-200mg, 20-150mg, 20-125mg, 20-100mg, 20-90mg, 20-80mg, 20-70mg, 20-60mg, 20-50mg, 20-40mg, 20-30mg;50-1500mg, 50-1000mg, 50-900mg, 50-800mg, 50-700mg, 50-600mg, 50-500mg, 50-400mg, 50-300mg, 50-250mg, 50-200mg, 50-150mg, 50-125mg, 5 0-100mg; 100-1500mg, 100-1000mg, 100-900mg, 100-800mg, 100-700mg, 100-600mg, 100-500mg, 100-400mg, 100-300mg, 100-250mg, 100-200mg. ;

[0352] This invention relates to a pharmaceutical composition or formulation comprising a therapeutically effective amount of the compound of the invention or its stereoisomers or pharmaceutically acceptable salts, as well as a carrier and / or excipients. The pharmaceutical composition may be in unit dosage form (the amount of the active ingredient in a unit dosage form is also referred to as a "dosage strength"). In some embodiments, the pharmaceutical composition includes, but is not limited to, 1-1500 mg, 5-1000 mg, 10-800 mg, 20-600 mg, 25-500 mg, 40-200 mg, 50-100 mg, 1 mg, 1.25 mg, 2.5 mg, 5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, etc. The compounds of the present invention, or their stereoisomers or pharmaceutically acceptable salts, in the following amounts: g, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg.

[0353] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of the compound of the present invention, its stereoisomer or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier and / or excipient, the therapeutically effective amount preferably being 1-1500 mg, wherein the disease is selected from autoimmune diseases, preferably rheumatoid arthritis, multiple sclerosis, and inflammatory gastroenteritis.

[0354] A method for treating a disease in a mammal. The method comprises administering a pharmaceutical compound of the invention, its stereoisomer or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier and / or excipient to a subject at a daily dose of 1-1500 mg / day. The daily dose may be a single dose or multiple doses. In some embodiments, the daily dose includes, but is not limited to, 10-1500 mg / day, 20-1500 mg / day, 25-1500 mg / day, 50-1500 mg / day, 75-1500 mg / day, 100-1500 mg / day, 200-1500 mg / day, 10-1000 mg / day, 20-1000 mg / day, 25-1000 mg / day, 50-1000 mg / day, 75-1000 mg / day, 100... -1000mg / day, 200-1000mg / day, 25-800mg / day, 50-800mg / day, 100-800mg / day, 200-800mg / day, 25-400mg / day, 50-400mg / day, 100-400mg / day, 200-400mg / day. In some embodiments, the daily dose includes, but is not limited to, 1mg / day, 5mg / day, 10mg / day, 20mg / day, 25mg / day, 50mg / day, 75mg / day, 100mg / day, 125mg / day, 150mg / day, 200mg / day, 400mg / day, 600mg / day, 800mg / day, 1000mg / day, 1200mg / day, 1400mg / day, and 1500mg / day.

[0355] This invention relates to a kit that may comprise a single-dose or multi-dose composition containing a compound of the present invention or its stereoisomers or a pharmaceutically acceptable salt thereof, wherein the amount of the compound of the present invention or its stereoisomers or a pharmaceutically acceptable salt thereof is the same as that in the pharmaceutical composition described above.

[0356] In this invention, the amount of the compound of the invention or its stereoisomer or pharmaceutically acceptable salt is converted in each case as a free base.

[0357] "Product specification" refers to the weight of the active pharmaceutical ingredient contained in each vial, tablet, or other unit of preparation.

[0358] Detailed description of the invention

[0359] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of any conflict, the definitions provided herein shall prevail. When trade names appear herein, they are intended to refer to the corresponding product or its active ingredient. All patents, published patent applications, and publications cited herein are incorporated herein by reference.

[0360] The term "alkyl" refers to a saturated, straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms, i.e., "C". 1-20 Alkyl group. The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (i.e., C12). 1-12 Alkyl groups, more preferably alkyl groups having 1 to 8 carbon atoms (i.e., C14-C ... 1-8 Alkyl groups, more preferably alkyl groups having 1 to 6 carbon atoms (i.e., C14-C6 ... 1-6 Alkyl groups, most preferably alkyl groups having 1 to 3 carbon atoms (i.e., C14-C ... 1-3 Alkyl groups). Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their various branched isomers, etc. The alkyl group can be substituted or unsubstituted. When substituted, the substituent can be replaced at any usable connection point. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C... 1-6 Alkyl, C2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0361] The term "alkylene" refers to divalent straight-chain and branched saturated alkyl groups. Examples of alkylene groups include, but are not limited to, methylene, ethylene, etc.

[0362] The term "alkenyl" refers to an alkyl group in which the molecule contains at least one carbon-carbon double bond, wherein the alkyl group, as defined above, has 2 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) carbon atoms (i.e., C atoms). 2-12 Alkenyl). The alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (i.e., C). 2-6 Alkenyl). Non-limiting examples include: vinyl, 1-propenyl, 2-propenyl, 2-methylpropenyl, 1-, 2-, or 3-butenyl, etc. The alkenyl group can be substituted or unsubstituted; when substituted, the substituent can be substituted at any usable connection point, preferably one or more of the following groups independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C. 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0363] The term "alkenyl" refers to a straight-chain or branched divalent unsaturated hydrocarbon group containing at least one carbon-carbon double bond (C=C). Unless otherwise specified, alkenyl groups contain 2-6 carbon atoms, preferably 2-4 carbon atoms. Non-limiting examples include alkenyl groups. The alkenyl groups may optionally be substituted with substituents.

[0364] The term "alkynyl" refers to a straight-chain or branched hydrocarbon group containing at least one carbon-carbon triple bond (C≡C), typically containing 2 to 18 carbon atoms, further containing 2 to 8 carbon atoms, further containing 2 to 6 carbon atoms, and further containing 2 to 4 carbon atoms. Examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 4-pentynyl, 3-pentynyl, 1-methyl-2-butynyl, 2-hexynyl, 3-hexynyl, 2-hepynyl, 3-hepynyl, 4-hepynyl, 3-octyynyl, 3-nonynyl, and 4-decynyl; the alkynyl group may optionally be substituted with substituents.

[0365] The term "ethynyl" refers to a straight-chain or branched divalent unsaturated hydrocarbon group containing a carbon-carbon triple bond (C≡C), typically containing 2-6 carbon atoms, and more commonly 2-4 carbon atoms. Non-limiting examples include ethynyl, propynyl, and butynyl, wherein the ethynyl group may optionally be substituted with substituents.

[0366] The term "carbocyclic" or "carbocyclic group" refers to a saturated, partially unsaturated, or aromatic carbocyclic ring, encompassing aryl and cycloalkyl groups. The carbocyclic ring can be monocyclic, bicyclic, or polycyclic, including bridged rings, fused rings, and spirocyclic rings, as well as combinations thereof. Carbocyclic rings typically have 3 to 12 carbon atoms, or 3 to 10 carbon atoms, or 3 to 6 carbon atoms. In non-limiting embodiments, monocyclic carbocyclic rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or phenyl, etc., and bicyclic bridged rings include... Etc., double-ring parallel rings include etc., double-ring spiral rings include In addition, the carbon ring can be optionally replaced by substituents.

[0367] The term "heterocycle" or "heterocyclic group" refers to a saturated or unsaturated, aromatic or non-aromatic ring containing one to four heteroatoms selected from N, O, or S and their oxidation states. It includes heteroaryl and heterocyclic alkyl groups. Heterocycles include monocyclic heterocycles, bicyclic bridged heterocycles, bicyclic fused heterocycles, and bicyclic spirocyclic heterocycles, or combinations thereof. They are typically 3- to 12-membered heterocycles, 5- to 12-membered heterocycles, or 5- to 7-membered heterocycles. Heterocyclic groups can be attached to heteroatoms or carbon atoms. Non-limiting examples include epoxyethyl, azirropropyl, oxacyclobutyl, azirrobutyl, 1,3-dioxopentyl, 1,4-dioxopentyl, 1,3-dioxohexyl, piperazine, azirroheptyl, pyridinyl, furanyl, thiophene, pyranyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyridazinyl, imidazoleyl, piperidinyl, piperinyl, morpholinyl, thiomorpholinyl, and 1,3-dithiayl. Dihydrofuranyl, dihydropyranyl, dithiapentylcycloyl, tetrahydrofuranyl, tetrahydropyrroleyl, tetrahydroimidazoyl, oxazolyl, dihydrooxazolyl, tetrahydrooxazolyl, tetrahydrothiazoyl, tetrahydropyranyl, benzimidazolyl, benzopyridyl, pyrrolopyridyl, benzodihydrofuranyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl and oxaspiro[3.3]heptyl, In addition, heterocyclic rings can be optionally substituted by substituents.

[0368] The term "alkynyl" refers to an alkyl group in a molecule that contains at least one carbon-carbon triple bond, wherein the alkyl group, as defined above, has 2 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) carbon atoms (i.e., C atoms). 2-12 The alkynyl group is preferably an alkynyl group having 2 to 6 carbon atoms (i.e., C64). 2-6 Alkyne group). Non-limiting examples include: ethynyl, propynyl, butynyl, pentylyl, hexynyl, etc. The alkynyl group can be substituted or unsubstituted; when substituted, the substituent can be substituted at any usable linking point. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C... 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0369] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic cyclic hydrocarbon substituent (i.e., monocyclic cycloalkyl) or polycyclic cyclic hydrocarbon substituent (i.e., polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms, i.e., C64. 3-20 Cycloalkyl group. The cycloalkyl group is preferably a cycloalkyl group having 3 to 12 carbon atoms (i.e., C12). 3-12 cycloalkyl groups, more preferably cycloalkyl groups having 3 to 8 carbon atoms (i.e., C14-C ... 3-8 Cycloalkyl groups, more preferably cycloalkyl groups having 3 to 6 carbon atoms (i.e., C164-C ... 3-6 (Cycloalkyl). Non-limiting examples of monocyclic cycloalkyl groups include: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, and cyclooctyl, etc. Non-limiting examples of polycyclic cycloalkyl groups include: spirocycloalkyl, fused cycloalkyl, and bridged cycloalkyl.

[0370] The term "spirocycloalkyl" refers to a polycyclic group in which the monocyclic rings share a single carbon atom (called the spiro atom). It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. It has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., C atoms). 5-20 Spirocycloalkyl. The spirocycloalkyl group is preferably a spirocycloalkyl group having 6 to 14 ring atoms (i.e., C14). 6-14 Spirocycloalkyl, more preferably spirocycloalkyl having 7 to 10 ring atoms (i.e., C14-C ... 7-10 Spirocycloalkyl. Based on the number of spiroatoms shared between rings, spirocycloalkyl is classified into monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl, preferably monospirocycloalkyl or bispirocycloalkyl, more preferably 3 / 4, 3 / 5, 3 / 6, 4 / 4, 4 / 5, 4 / 6, 5 / 3, 5 / 4, 5 / 5, 5 / 6, 5 / 7, 6 / 3, 6 / 4, 6 / 5, 6 / 6, 6 / 7, 7 / 5, or 7 / 6 monospirocycloalkyl.

[0371] The term "fused-ring cycloalkyl" or "tert-ring cycloalkyl" refers to a fully carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with the other rings in the system, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., C atoms). 5-20 Fused cyclic alkyl groups. They may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably, the fused cyclic alkyl group has 6 to 14 ring atoms (i.e., C14).6-14 Fused cyclic alkyl groups, more preferably fused cyclic alkyl groups having 7 to 10 ring atoms (i.e., C14-C ... 7-10 Fused cyclic alkyl groups are classified into bicyclic, tricyclic, tetracyclic, or polycyclic fused cyclic alkyl groups based on the number of constituent rings. Bicyclic or tricyclic fused cyclic alkyl groups are preferred, and ternary / quadrivalent, ternary / quinary, ternary / sixary, quadrivalent / quadrivalent, quadrivalent / quinary, quadrivalent / sixary, quinary / trivalent, quinary / quadrivalent, quinary / quinary, quinary / sixary, quinary / sevenary, quinary / trivalent, quinary / quadrivalent, quinary / quadrivalent, quinary / sixary, quinary / sevenary, quinary / trivalent, quinary / quadrivalent, quinary / sixary, quinary / sevenary, quinary / trivalent, or quinary / sixary bicyclic fused cyclic alkyl groups are more preferred.

[0372] The term "bridged cycloalkyl" refers to a fully carbon polycyclic group in which any two rings share two non-directly connected carbon atoms, having 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., C atoms). 5-20 Bridged cycloalkyl groups. They contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. Preferably, the bridged cycloalkyl group has 6 to 14 ring atoms (i.e., C14). 6-14 Bridged cycloalkyl groups, more preferably bridged cycloalkyl groups having 7 to 10 ring atoms (i.e., C14-C ... 7-10 Bridged cycloalkyl groups are classified into bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl groups based on the number of rings, with bicyclic or tricyclic bridged cycloalkyl groups being preferred. Example structures are shown below:

[0373] The cycloalkyl group can be fused to an aryl, heteroaryl, or heterocycloalkyl ring, wherein the ring linked to the parent structure is a cycloalkyl group. The cycloalkyl group can be optionally substituted or unsubstituted; when substituted, the substituent can be substituted at any usable connection point. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C... 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0374] The term "heterocyclic alkyl" refers to a saturated or partially unsaturated monocyclic heterocyclic hydrocarbon substituent (i.e., monocyclic heterocyclic alkyl) or polycyclic heterocyclic hydrocarbon substituent (i.e., polycyclic heterocyclic alkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 3-20 membered heterocyclic alkyl), wherein one or more (e.g., 1, 2, 3 or 4) ring atoms are selected from N, O, P, Si, Se, S or B and heteroatoms of their oxidation states, but excluding the ring moiety of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. The heterocyclic alkyl group preferably has 3 to 12 ring atoms (i.e., 3-12 membered heterocyclic alkyl groups), wherein it contains 1 to 4 heteroatoms selected from N, O, S and P atoms; more preferably it has 4 to 8 ring atoms (i.e., 4-8 membered heterocyclic alkyl groups), wherein it contains 1 to 4, 1 to 3 or 1 to 2 heteroatoms selected from N, O, S and P atoms; even more preferably it has 3 to 6 ring atoms (i.e., 3-6 membered heterocyclic alkyl groups), wherein it contains 1 to 4, 1 to 3 or 1 to 2 heteroatoms selected from N, O, S and P atoms; and most preferably it has 4 to 6 ring atoms (i.e., 4-6 membered heterocyclic alkyl groups), wherein it contains 1 to 4, 1 to 3 or 1 to 2 heteroatoms selected from N, O, S and P atoms. Non-limiting examples of the monocyclic heterocyclic alkyl groups include: azirrobutyl, oxacyclobutyl, thiohexacyclobutyl, pyrrolyl, imidazoalkyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydroimidazoyl, dihydrofuranyl, dihydropyrazolyl, piperidinyl, piperazinyl, morpholinyl, 1,3-dioxocyclopentyl, 2,2-difluoro-1,3-dioxocyclopentyl, cyclopentanone, 2,2-difluorocyclopentanone, acrylonitrile, oxacyclopentyl, azirropentyl, tetrahydropyrrolyl, butyrolactam, valeronyl, or caprolactam, etc. Example structures are as follows:

[0375] Non-limiting examples of the polycyclic heterocyclic alkyl groups include spirocyclic alkyl groups, fused heterocyclic alkyl groups, and bridged heterocyclic alkyl groups.

[0376] The term "spiroheteroalkyl" refers to a polycyclic heterocyclic alkyl group that shares a single atom (called a spiro atom) between monocyclic rings, having 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 5-20-membered spiroheteroalkyl), wherein one or more (e.g., 1, 2, 3, or 4) ring atoms are selected from heteroatoms of N, O, P, Si, Se, S, or B and their oxidation states, but excluding the -OO-, -OS-, or -SS- ring moieties, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a fully conjugated π-electron system. The spiroheteroalkyl group is preferably a spiroheteroalkyl group having 6 to 14 ring atoms (i.e., 6-14-membered spiroheteroalkyl), more preferably a spiroheteroalkyl group having 7 to 10 ring atoms (i.e., 7-10-membered spiroheteroalkyl). The spiroheterocyclic alkyl group is classified into monospiroheterocyclic alkyl, bispiroheterocyclic alkyl, or polyspiroheterocyclic alkyl based on the number of spiro atoms shared between the rings. It is preferred to be monospiroheterocyclic alkyl or bispiroheterocyclic alkyl, and more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered monospiroheterocyclic alkyl.

[0377] The term "fused heterocyclic alkyl" or "fused heterocyclic alkyl" refers to a polycyclic heterocyclic alkyl group in which each ring in a system shares an adjacent pair of atoms with other rings in the system. This group has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 5-20-membered fused heterocyclic alkyl), wherein one or more (e.g., 1, 2, 3, or 4) ring atoms are selected from heteroatoms of N, O, P, Si, Se, S, or B and their oxidation states, but excludes the -OO-, -OS-, or -SS- ring moieties, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a fully conjugated π-electron system. The fused heterocyclic alkyl is preferably a fused heterocyclic alkyl with 6 to 14 ring atoms (i.e., 6-14-membered fused heterocyclic alkyl), more preferably a fused heterocyclic alkyl with 7 to 10 ring atoms (i.e., 7-10-membered fused heterocyclic alkyl). Based on the number of constituent rings, they are classified as bicyclic, tricyclic, tetracyclic, or polycyclic heterocyclic alkyl groups, with bicyclic or tricyclic heterocyclic alkyl groups being preferred, and ternary / quadrivalent, ternary / quinary, ternary / sixary, quadrivalent / quadrivalent, quadrivalent / quinary, quadrivalent / quinary, quadrivalent / sixary, quinary / trivalent, quinary / quadrivalent, quinary / quinary, quinary / sixary, quinary / sevenary, quinary / trivalent, quinary / quadrivalent, quinary / quadrivalent, quinary / sixary, quinary / sevenary, quinary / trivalent, quinary / quadrivalent, quinary / sixary, quinary / sevenary, quinary / trivalent, or quinary / sixary bicyclic heterocyclic alkyl groups.

[0378] The term "bridged heterocyclic alkyl" refers to a polycyclic heterocyclic alkyl group in which any two rings share two non-directly connected atoms, having 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 5-20-membered bridged heterocyclic alkyl), wherein one or more (e.g., 1, 2, 3, or 4) ring atoms are selected from heteroatoms of N, O, P, Si, Se, S, or B and their oxidation states, but excluding the -OO-, -OS-, or -SS- ring moieties, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a fully conjugated π-electron system. The bridged heterocyclic alkyl is preferably a bridged heterocyclic alkyl with 6 to 14 ring atoms (i.e., 6-14-membered bridged heterocyclic alkyl), more preferably a bridged heterocyclic alkyl with 7 to 10 ring atoms (i.e., 7-10-membered bridged heterocyclic alkyl). Based on the number of constituent rings, they are classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic alkyl groups, with bicyclic bridged heterocyclic alkyl groups or tricyclic bridged heterocyclic alkyl groups being preferred.

[0379] The heterocyclic alkyl group can be fused to an aryl, heteroaryl, or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic alkyl group.

[0380] The heterocyclic alkyl group may be optionally substituted or unsubstituted. When substituted, the substituent may be substituted at any usable linker. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, and C. 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0381] The term "aryl" refers to an all-carbon monocyclic group (i.e., monocyclic aryl) or a fused polycyclic group (i.e., polycyclic aryl) having a conjugated π-electron system, having 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, or 14) carbon atoms (i.e., C atoms). 6-14 Aryl group). The aryl group is preferably an aryl group having 6 to 12 carbon atoms (i.e., C64). 6-12 Aryl), more preferably aryl having 6 to 10 carbon atoms (i.e., C10). 6-10 Aryl), further preferably phenyl or naphthyl, most preferably phenyl. The monocyclic aryl group is, for example, phenyl. Non-limiting examples of the polycyclic aryl group include: naphthyl, anthracene, phenanthrene, etc.

[0382] The aryl group can be fused to a cycloalkyl or heterocycloalkyl ring to form a fused aromatic ring system, wherein the ring connected to the parent structure is an aryl ring. The fused aromatic ring system is preferably a 6-10-membered aryl-3-8-membered cycloalkyl or a 6-10-membered aryl-4-8-membered heterocycloalkyl, more preferably a phenyl-4-8-membered cycloalkyl or a phenyl-4-8-membered heterocycloalkyl, and even more preferably a phenyl-4-6-membered cycloalkyl or a phenyl-4-6-membered heterocycloalkyl. Non-limiting examples include: indolyl, inzolyl, quinolinyl, isoquinolinyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, thiophene, quinazolinyl, benzothiazolyl, carbazole, thiophenepyridyl, pyridothiophenyl, pyridopyrroleyl, etc. Example structures are as follows:

[0383] The aryl group can be optionally substituted or unsubstituted. When substituted, the substituent can be replaced at any usable linker. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C... 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0384] The term "heteroaryl" refers to a monocyclic heteroaryl group (i.e., monocyclic heteroaryl) or a fused polycyclic heteroaryl group (i.e., polycyclic heteroaryl) having a conjugated π-electron system, having 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., 5-14-membered heteroaryl), wherein one or more (e.g., 1, 2, 3, or 4) ring atoms are heteroatoms selected from N, O, P, Si, Se, S, or B and their oxidation states, preferably heteroatoms selected from nitrogen, oxygen, or sulfur, but excluding the -OO-, -OS-, or -SS- ring moieties, and the remaining ring atoms are carbon or C(O). The heteroaryl is preferably a heteroaryl having 5 to 10 ring atoms (i.e., 5-10-membered heteroaryl). The monocyclic heteroaryl group is preferably a heteroaryl group having 5 to 6 ring atoms (i.e., a 5-6 membered heteroaryl group). Non-limiting examples include: furanyl, pyranyl, thiophene, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazole, pyrazolyl, triazolyl, tetrazolyl, pyrroleyl, pyridinyl, pyrimidinyl, pyridoneyl, pyrazinyl, pyridazinyl, etc.

[0385] The heteroaryl group can be fused to an aryl, heterocyclic alkyl, or cycloalkyl ring to form a fused heteroaryl ring system, wherein the ring connected to the parent structure can be a heteroaryl ring or an aryl ring. Preferably, the fused heteroaryl ring system is a 5-6 membered heteroaryl-5-6 membered heteroaryl or a 5-10 membered heteroaryl-C 6-10 Aryl or C 6-10 The aryl group comprises 5-10 heteroaryl groups, with 5-6 heteroaryl-5-6 heteroaryl groups, 5-6 heteroaryl-phenyl groups, or phenyl-5-6 heteroaryl groups being more preferred. Non-limiting examples include: indolyl, indazole, quinolinyl, isoquinolinyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophene, thienophenyl, quinazolinyl, benzothiazolyl, carbazole, thienopyridyl, pyridothiophene, pyridopyrroleyl, etc. Example structures are as follows:

[0386] The heteroaryl group can be optionally substituted or unsubstituted. When substituted, the substituent can be substituted at any usable linker. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C... 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0387] The term "alkoxy" refers to -O- (alkyl) or -O- (unsubstituted cycloalkyl), wherein alkyl and cycloalkyl are defined as above, having 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms (i.e., C atoms). 1-10 Alkoxy group). The alkoxy group is preferably an alkoxy group having 1 to 8 carbon atoms (i.e., C14). 1-8 Alkoxy groups, more preferably alkoxy groups having 1 to 6 carbon atoms (i.e., C14-C6 ... 1-6 Alkoxy groups, preferably alkoxy groups having 1 to 3 carbon atoms (i.e., C14-C ... 1-3 Alkoxy groups. Non-limiting examples include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexyloxy, etc. The alkoxy group may be optionally substituted or unsubstituted; when substituted, the substituent may be substituted at any usable linking point, preferably one or more of the following groups independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C 1-6 Alkyl, C2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0388] The term "alkathioyl" refers to -S- (alkyl) or -S- (unsubstituted cycloalkyl), wherein alkyl and cycloalkyl are defined as above and have 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms (i.e., C atoms). 1-10 Alkylthio group). The alkylthio group is preferably an alkylthio group having 1 to 8 carbon atoms (i.e., C12). 1-8 Alkylthioyl), more preferably alkylthioyl groups having 1 to 6 carbon atoms (i.e., C14-C ... 1-6 Alkylthio group), preferably alkylthio group with 1 to 3 carbon atoms (i.e., C12-C ... 1-3 Alkylthioyl). Non-limiting examples include: methylthioyl, ethylthioyl, propylthioyl, butylthioyl, cyclopropylthioyl, cyclobutylthioyl, cyclopentylthioyl, cyclohexylthioyl, etc. The alkylthioyl group may be optionally substituted or unsubstituted. When substituted, the substituent may be substituted at any usable linking point. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C... 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0389] The terms “halogen” or “halogenated” should be understood to refer to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) atoms, preferably fluorine, chlorine or bromine atoms.

[0390] The term "halogenated alkyl" refers to an alkyl group substituted with one or more halogens, wherein the alkyl group is as defined above. Non-limiting examples include: fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, chlorofluoromethyl, dichloromethyl, bromofluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, bromodifluoromethyl, bromochlorofluoromethyl, dibromofluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-difluoroethyl, 2-chloro-2-fluoroethyl, 2,2-dichloroethyl, 2-bromo-2-fluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2-dichloro-2-fluoroethyl, 2, 2,2-Trichloroethyl, 2-bromo-2,2-difluoroethyl, 2-bromo-2-chloro-2-fluoroethyl, 2-bromo-2,2-dichloroethyl, 1,1,2,2-tetrafluoroethyl, pentafluoroethyl, 1-chloro-1,2,2,2-tetrafluoroethyl, 2-chloro-1,1,2,2-tetrafluoroethyl, 1,2-dichloro-1,2,2-trifluoroethyl, 2-bromo-1,1,2,2-tetrafluoroethyl, etc., preferably fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-difluoroethyl. The alkyl halogroup may be optionally substituted or unsubstituted. When substituted, the substituent may be substituted at any usable linking point. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0391] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein the alkoxy group is as defined above. Non-limiting examples include: fluoromethoxy, chloromethoxy, bromomethoxy, iodomethoxy, difluoromethoxy, chlorofluoromethoxy, dichloromethoxy, bromofluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, dichlorofluoromethoxy, trichloromethoxy, bromodifluoromethoxy, bromochlorofluoromethoxy, dibromofluoromethoxy, etc.; preferably fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2,2-difluoroethoxy, 2-chloro-2-fluoroethoxy, 2,2-dichloroethoxy, 2-bromo-2-fluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2 2-Dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, 2-bromo-2,2-difluoroethoxy, 2-bromo-2-chloro-2-fluoroethoxy, 2-bromo-2,2-dichloroethoxy, 1,1,2,2-tetrafluoroethoxy, pentafluoroethoxy, 1-chloro-1,2,2,2-tetrafluoroethoxy, 2-chloro-1,1,2,2-tetrafluoroethoxy, 1,2-dichloro-1,2,2-trifluoroethoxy, 2-bromo-1,1,2,2-tetrafluoroethoxy, preferably fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2,2-difluoroethoxy. The haloalkoxy group may be optionally substituted or unsubstituted. When substituted, the substituent may be substituted at any usable linker. The substituent is preferably one or more of the following groups, independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, oxo, C... 1-6 Alkyl, C 2-6 alkenyl, ynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 alkylamine group, C 3-8 Cycloalkyl, 4-8 membered heterocyclic alkyl, C 6-10 Aryl or 5-10 heteroaryl compounds.

[0392] The term "thiol" refers to -SH.

[0393] The term "hydroxyl group" refers to -OH.

[0394] The term "nitro" refers to -NO2.

[0395] The term "amino" refers to -NH2.

[0396] The term "cyano" refers to -CN.

[0397] The term "carboxyl group" refers to -C(O)OH.

[0398] The term "oxo" or "oxo group" refers to =O.

[0399] The term "carbonyl" refers to C=O.

[0400] The term "aminoacyl" refers to -C(O)NH2.

[0401] The term “deuterated alkyl” refers to an alkyl group that is substituted with one or more deuterium atoms, wherein the alkyl group is as defined above.

[0402] The term "hydroxyalkyl" refers to an alkyl group that is substituted with one or more hydroxyl groups, wherein the alkyl group is as defined above.

[0403] The terms “comprising,” “including,” “having,” “containing,” or “involving,” and their other variations herein, are inclusive or open-ended and do not exclude other elements or method steps not listed. Those skilled in the art will understand that the foregoing term “comprising” encompasses the meaning of “consisting of.”

[0404] The term "one or more species" or similar expression "at least one species" can mean, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more species.

[0405] When the lower and upper limits of a numerical range are disclosed, any numerical value falling within that range and any included range are specifically disclosed. In particular, each range of values ​​disclosed herein should be understood as representing each numerical value and range encompassed within a wider range.

[0406] In this article, "Z" and "-Z-" both refer to the same specific group and can be used interchangeably.

[0407] The expression "mn" used in this paper refers to the range from m to n, the subrange consisting of the individual point values ​​within it, and the individual point values ​​themselves. For example, the expression "C2-C8" or "C 2-8 "Covering a range of 2-8 carbon atoms, and should be understood to also include any subranges within this range and each point value, such as C2-C5, C3-C4, C2-C6, C3-C6, C4-C6, C4-C7, C4-C8, etc., and C2, C3, C4, C5, C6, C7, C8, etc. For example, the expression "C3-C..." 10 "or "C 3-10 "It should also be understood in a similar way, for example, it can cover any subrange and point value contained therein, such as C3-C9, C6-C9, C6-C8, C6-C7, C7-C..." 10 C7-C9, C7-C8, C8-C9, etc., as well as C3, C4, C5, C6, C7, C8, C9, C 10 For example, stating "C1-C6" or "C..."1-6 "The term 'covers' the range of 1-6 carbon atoms and should be understood to also include any subranges within this range and each point value, such as C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5, C1-C6, and C1, C2, C3, C4, C5, C6, etc. Similarly, the expression 'ternary to decaary' should be understood to include any subrange within this range and each point value, such as ternary to pentary, ternary to hexaary, ternary to octary, quaternary to pentary, quaternary to hexaary, quaternary to octary, pentary to octary, pentary to octary, pentary to octary, pentary to octary, pentary to octary, pentary to octary, pentary to octary, pentary to octary, octary to octary, quinary to decaary, etc., and tri-, quadri-, quinary, quinary, quinary, quinary, octary, quinary, octary, quinary, decaary, etc. Other similar expressions in this text should also be understood in a similar manner."

[0408] The different expressions used in this article, such as "X is selected from A, B or C", "X is selected from A, B and C", "X is A, B or C", and "X is A, B and C", all express the same meaning, that is, X can be any one or more of A, B, and C.

[0409] The terms “optional” or “optionally” mean that an event or condition described below may or may not occur, including both the occurrence and non-occurrence of the event or condition. For example, “optionally (al) alkyl-substituted cycloalkyl” means that an alkyl group may but is not required to be present, and this description includes cases where the cycloalkyl group is substituted with an alkyl group and cases where the cycloalkyl group is not substituted with an alkyl group.

[0410] The terms "substitution" and "substituted" refer to the selective replacement of one or more (e.g., one, two, three, or four) hydrogen atoms on a specified atom by a designated group, provided that the substitution does not exceed the normal valence of the specified atom in the present case and the substitution forms a stable compound. Combinations of substituents and / or variables are permitted only if such combinations form a stable compound. When describing the absence of a substituent, it should be understood that the substituent can be one or more hydrogen atoms, provided that the structure allows the compound to reach a stable state. When describing the optional substitution of each carbon atom in a group with heteroatoms, the condition is that the substitution does not exceed the normal valence of all atoms in the group in the present case and a stable compound is formed. Furthermore, when a structural unit is substituted, even if the structural unit is specified as having hydrogen atoms, it does not mean that the hydrogen atom cannot be substituted, but rather that any position in the structural unit including the hydrogen atom can be substituted. For example, structural unit "Substituted" means that any position of the nitrogen atom, including the hydrogen atom, can be substituted.

[0411] If a substituent is described as "optionally...substituted," the substituent may be unsubstituted or substituted. If an atom or group is described as being optionally substituted by one or more of the substituents in the list, one or more hydrogen atoms on that atom or group may be replaced by independently selected, optional substituents. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are substituted. When the substituent is hydrogen, this may also indicate that the corresponding group is "unsubstituted" or "unsubstituted." Unless otherwise specified, as used herein, the connection point of a substituent may be derived from any suitable position of the substituent.

[0412] When the bond of a substituent is such that it passes through the ring and connects two atoms, then such a substituent can be bonded to any cyclic atom in the substituted ring.

[0413] When any variable (e.g., R), and labeled variables (e.g., R1, R2, R3, R4, R5, R6, R7, etc.) appear more than once in the composition or structure of a compound, their definition is independent for each occurrence in each case. For example, if a group is substituted by 0, 1, 2, 3, or 4 R substituents, the group may optionally be substituted by up to four R substituents, and the options for each R substituent in each case are independent of each other.

[0414] The compounds of this invention include their racemic, stereoisomer, tautomer, deuterated, isotopic compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts, or cocrystals.

[0415] The term "isomer" includes "stereoisomer" and "tautomer." A stereoisomer is a molecule whose atoms or groups of atoms are connected in the same order but arranged differently in space. Stereoisomers include cis-trans isomers and optical isomers. A tautomer is a molecule that can interconvert through a reversible chemical reaction called tautomerization, typically caused by the migration of hydrogen atoms and π bonds (double or triple bonds), resulting in a transformation from one functional group to another. Examples include the following paired compounds: aldehyde / ketone-enol, imine-enamine.

[0416] The compounds of this invention can exist in specific geometric or stereoisomeric forms. All such compounds of this invention, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof, as well as other mixtures, such as mixtures enriched with enantiomers or diastereomers, are within the scope of this invention. Additional asymmetric carbon atoms may be present in the substituents of the compounds of this invention. All such isomers and mixtures thereof are included within the scope of this invention. In some embodiments, the preferred compounds are those isomers exhibiting superior biological activity. Purified or partially purified isomers and stereoisomers of the compounds of this invention, or racemic mixtures or diastereomer mixtures, are also included within the scope of this invention. Purification and separation of such substances can be achieved using standard techniques known in the art.

[0417] All hydrogen atoms described in this invention can be replaced by their isotope deuterium, and any hydrogen atom in the compounds of the embodiments of this invention can also be replaced by a deuterium atom.

[0418] The compounds of this invention include all suitable isotopic derivatives thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of this disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, respectively. 2 H (deuterium, D) 3 H (tritium, T) 11 C 13 C 14 C 15 N、 17 O、 18 O、 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl、 82 Br、 123 I, 124 I, 125 I, 129 I and 131 Grade I, with deuterium as the preferred grade.

[0419] Compared to undeuterated drugs, deuterated drugs offer advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, regardless of radioactivity, are included within the scope of this disclosure. Each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom, wherein the deuterium substitution can be partial or complete; partial deuterium substitution refers to the replacement of at least one hydrogen atom with at least one deuterium atom.

[0420] In the compounds of this invention, when a position is specifically designated as deuterium D, that position should be understood as having a deuterium abundance at least 1000 times greater than the native abundance (which is 0.015%) (i.e., at least 15% deuterium doping). In some embodiments, the deuterium abundance per designated deuterium atom is at least 1000 times greater than the native abundance of deuterium (i.e., at least 15% deuterium doping). In some embodiments, the deuterium abundance per designated deuterium atom is at least 2000 times greater than the native abundance of deuterium (i.e., at least 30% deuterium doping). In some embodiments, the deuterium abundance per designated deuterium atom is at least 3000 times greater than the native abundance of deuterium (i.e., at least 45% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 3340 times greater than the natural deuterium abundance (i.e., at least 50.1% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 3500 times greater than the natural deuterium abundance (i.e., at least 52.5% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 4000 times greater than the natural deuterium abundance (i.e., at least 60% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 4500 times greater than the natural deuterium abundance (i.e., at least 67.5% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 5000 times greater than the natural deuterium abundance (i.e., at least 75% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 5500 times greater than the natural deuterium abundance (i.e., at least 82.5% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6000 times greater than the natural deuterium abundance (i.e., at least 90% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6333.3 times greater than the natural deuterium abundance (i.e., at least 95% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6466.7 times greater than the natural deuterium abundance (i.e., at least 97% deuterium doping). In some embodiments, the deuterium abundance of each designated deuterium atom is at least 6600 times greater than the natural deuterium abundance (i.e., at least 99% deuterium doping). In some implementations, the abundance of deuterium in each designated deuterium atom is at least 6633.3 times greater than the natural abundance of deuterium (i.e., at least 99.5% deuterium doping).

[0421] The term "pharmaceutically acceptable" refers to a substance that, within the bounds of normal medical judgment, is suitable for contact with a patient's tissues without causing undue toxicity, irritation, allergic reactions, etc., has a reasonable benefit-risk ratio, and is effective for its intended use.

[0422] The term "pharmaceutically acceptable salt" refers to a salt of the compounds of the present invention that is safe and effective when used in mammals and has the intended biological activity.

[0423] The term "pharmaceutical composition" refers to a composition containing one or more compounds described in this invention, or their physiologically / pharmaceutically acceptable salts or prodrugs, as well as other components such as physiologically / pharmaceutically acceptable carriers or excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and enabling it to exert its biological activity.

[0424] The term "pharmaceutically acceptable carrier" refers to substances that do not cause significant irritation to the organism and do not impair the biological activity and properties of the active compound. "Pharmaceutically acceptable carriers" include, but are not limited to, glidants, sweeteners, diluents, preservatives, dyes / colorants, flavoring agents, surfactants, wetting agents, dispersants, disintegrants, stabilizers, solvents, or emulsifiers.

[0425] "Excipient" refers to an agent that is not itself a therapeutic agent but is used as a diluent, binder, and / or medium to be added to a pharmaceutical composition to improve its disposal or storage properties or to allow or promote the formation of a unit dosage form of the compound or pharmaceutical composition for administration. As is known to those skilled in the art, pharmaceutical excipients can provide a variety of functions and can be described as wetting agents, buffers, suspending agents, lubricants, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavoring agents, and sweeteners. Examples of pharmaceutical excipients include, but are not limited to: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, and croscarmellose (e.g., sodium croscarmellose); (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter. (9) Oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) Diols, such as propylene glycol; (11) Polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) Esters, such as ethyl oleate and ethyl laurate; (13) Agar; (14) Buffers, such as magnesium hydroxide and aluminum hydroxide; (15) Alginate; (16) Atherless water; (17) Isotonic saline; (18) Ringer's solution; (19) Ethanol; (20) pH buffer solution; (21) Polyesters, polycarbonates and / or polyanhydrides; and (22) Other non-toxic compatible substances used in pharmaceutical preparations.

[0426] The terms "administration" or "giving" refer to methods that enable the delivery of a compound or composition to a desired biological site of action. These methods include, but are not limited to, oral or parenteral administration (including intraventricular, intravenous, subcutaneous, intraperitoneal, intramuscular, and intravascular injection or infusion), local administration, and rectal administration. In particular, injection or oral administration.

[0427] As used herein, the term "treatment" includes relieving, reducing, or improving a disease or symptom; preventing other symptoms; improving or preventing underlying metabolic factors of symptoms; inhibiting a disease or symptom, for example, preventing the development of a disease or symptom; reducing a disease or symptom; promoting the remission of a disease or symptom; or causing the symptom of a disease or symptom to cease; and extends to include prevention. "Treatment" also includes achieving therapeutic and / or preventive benefits. A therapeutic benefit refers to the eradication or improvement of the condition being treated. Furthermore, a therapeutic benefit is achieved by eradicating or improving one or more physical symptoms associated with an underlying disease, and an improvement in the patient's condition can be observed even though the patient may still have the underlying disease. A preventive benefit refers to the use of a composition by a patient to prevent the risk of a certain disease, or the use by a patient when experiencing one or more physical symptoms of a disease, even though the disease has not yet been diagnosed.

[0428] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that can effectively treat or prevent a target disorder, disease, or symptom. The term "neuropsychiatric disorders" is a collective term for neurological and psychiatric disorders, encompassing both neurological and / or psychiatric conditions.

[0429] For the purposes of pharmaceuticals, pharmaceutical units, or active ingredients, the terms "effective amount," "therapeutic effective amount," or "preventive effective amount" refer to a sufficient quantity of a drug or agent that provides acceptable side effects while achieving the desired therapeutic effect. The determination of the effective amount varies from person to person, depending on the individual's age and general condition, as well as the specific active substance. The appropriate effective amount in a given case can be determined by a person skilled in the art based on routine testing.

[0430] As used herein, “individual” includes both human and non-human animals. Exemplary human individuals include human individuals suffering from a disease (such as the disease described herein) (referred to as patients) or normal individuals. In this invention, “non-human animals” includes all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock, and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).

[0431] The term "room temperature" refers to a temperature ranging from 10°C to 40°C. In some embodiments, "room temperature" refers to a temperature ranging from 15°C to 30°C; in other embodiments, "room temperature" refers to a temperature ranging from 18°C ​​to 25°C.

[0432] "Equivalent" or its abbreviation "eq" is the equivalent amount of other raw materials required based on the equivalence relationship of a chemical reaction, using the basic raw materials used in each step as a reference (1 equivalent).

[0433] In the context of this invention, when the terms "about" or "approximately" are used, whether or not they are used, it means within 10% of a given value or range, appropriately within 5%, and particularly within 1%. Alternatively, for those skilled in the art, the terms "about" or "approximately" mean within an acceptable standard error of the average. Whenever a number with a value of N is disclosed, any number having a value within N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, or N+ / -10% is explicitly disclosed, where "+ / -" refers to addition or subtraction.

[0434] The following detailed description of the invention is intended to illustrate non-limiting embodiments, enabling other skilled in the art to more fully understand the technical solutions, principles, and practical applications of the invention, so that other skilled in the art can modify and implement the invention in many forms to best suit the requirements of a particular application. Detailed Implementation

[0435] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Furthermore, it should be understood that after reading the teachings of this invention, those skilled in the art can make various alterations or modifications to the invention, and these equivalent forms also fall within the scope defined by the appended claims.

[0436] Example

[0437] The embodiments of the present invention will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be considered as limiting the scope of the invention. Unless otherwise specified, specific conditions in the examples are performed under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used, unless otherwise specified, are all commercially available conventional products. Unless otherwise specified, all proportions or percentages used herein are by weight.

[0438] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰ increments. -6 The unit (ppm) is given. NMR measurements were performed using a Bruker Avance III 400 and Bruker Avance 300 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).

[0439] MS determination was performed using (Agilent 6120B (ESI) and Agilent 6120B (APCI));

[0440] HPLC determinations were performed using an Agilent 1260DAD high-performance liquid chromatograph (Zorbax SB-C18 100×4.6mm, 3.5μM).

[0441] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) are 0.15mm-0.20mm in diameter, and the silica gel plates used for thin-layer chromatography separation and purification are 0.4mm-0.5mm in diameter.

[0442] Column chromatography typically uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.

[0443] Abbreviation Explanation:

[0444] NaH: Sodium hydride (60% content);

[0445] DMF: N,N-dimethylformamide;

[0446] RuPhos Pd G3: Methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II);

[0447] XPhos: 2-Dicyclohexylphosphine-2′,4′,6′-triisopropylbiphenyl;

[0448] Pd(dppf)Cl2: 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride;

[0449] DDQ: 2,3-Dichloro-5,6-dicyanobenzoquinone;

[0450] XPhos Pd G2: Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II);

[0451] XantPhos: 4,5-bisdiphenylphosphine-9,9-dimethyloxanthracene;

[0452] DIPEA: N,N-diisopropylethylamine;

[0453] CNBr: Cyanide bromide;

[0454] EA: Ethyl acetate;

[0455] Cs2CO3: Cesium carbonate;

[0456] DMSO: Dimethyl sulfoxide;

[0457] Pd2(dba)3: Tris(dibenzylacetone)dipalladium;

[0458] K3PO4: Potassium phosphate.

[0459] HPLC analysis method A:

[0460] Chromatographic column: Yuexu; Column model: Ultimate C18 4.6*50mm, 3μm; Chromatographic conditions: Detection wavelength: 254nm / 210nm; Flow rate: 1.0ml / min; Column temperature: 35℃; Injection volume: 2μl; Acquisition time: 10min; Mobile phase A: 0.05% TFA solution; Mobile phase B: acetonitrile.

[0461] Gradient elution procedure:

[0462] Example 1:

[0463] Step 1: Compound 1A (5 g, 38.89 mmol) was dissolved in 1,4-dioxane (40 mL) and acetic acid (20 mL). Compound 1B (7.36 g, 42.78 mmol) was added at room temperature, and the mixture was heated to 100 °C and stirred for 6 h. After the reaction was complete, the mixture was cooled to room temperature, filtered, and the filter cake was poured into water. The pH was adjusted to 7-8 with a saturated sodium bicarbonate solution, and the mixture was extracted with ethyl acetate. The organic phase was concentrated under reduced pressure to obtain compound 1C (4.2 g, yield 40.89%).

[0464] LC-MS(ESI): m / z = 264.0 [M+H] + .

[0465] Step 2: 1C (500 mg, 1.89 mmol) was dissolved in DMF (5 mL), and NaH (5.67 mmol) was added in portions under a nitrogen atmosphere. After reacting at room temperature for 0.5 h, 1D (877.34 mg, 3.78 mmol) was slowly added, and the temperature was then raised to 60 °C and the reaction continued for 16 h. After the reaction was complete, the reaction solution was slowly poured into ice water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain compound 1E (200 mg, 30.52%).

[0466] LC-MS (ESI): m / z = 346.0 [M+H] + .

[0467] Step 3: Compound 1E (100 mg, 0.29 mmol) was dissolved in 1,4-dioxane (10 mL) and water (1 mL), followed by the sequential addition of compound 1H (121.67 mg, 0.35 mmol) (prepared according to the method described in patent WO2024151547), potassium phosphate (184.67 mg, 0.87 mmol), Ruphos Pd G3 (24.25 mg, 0.029 mmol), and X-phos (27.65 mg, 0.058 mmol). After the addition was complete, nitrogen gas was introduced, and the mixture was heated to 100 °C for 3 hours. After the reaction was complete, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was then subjected to reverse-phase medium-pressure reaction to obtain compound 1 (30 mg, 21.24%).

[0468] LC-MS (ESI): m / z = 489.2 [M+H] + .

[0469] 1H NMR (400MHz, DMSO-d6): δ10.91(s,1H),8.34-8.30(m,2H),7.50-7.35(m,7H),4.96-4.86(m,2H),4.41- 4.33(m,1H),2.87-2.75(m,1H),2.60-2.52(m,1H),2.41-2.28(m,1H),2.15(s,3H),2.12-2.04(m,1H).

[0470] Example 2:

[0471] Step 1: Compound 2A (1 g, 5.71 mmol) was dissolved in dichloromethane (10 mL), and phosphorus tribromide (0.53 g, 1.94 mmol) was slowly added at room temperature. The reaction was carried out at 25 °C for 2 h. After the reaction was completed, the solution was poured into water, the pH was adjusted to 7-8 with saturated sodium bicarbonate solution, and the mixture was extracted with ethyl acetate. The organic phase was concentrated under reduced pressure to obtain compound 2B (0.6 g, yield 44.14%).

[0472] LC-MS (ESI): m / z = 237.9 [M+H] + .

[0473] Step 2: 2B (0.4 g, 1.68 mmol), 4-iodophenol (0.44 g, 2.02 mmol), and potassium carbonate (0.70 g, 5.04 mmol) were dissolved in acetonitrile (10 mL) and reacted at 70 °C for 5 h. After the reaction was complete, the mixture was filtered, and the organic phase was concentrated under reduced pressure. The residue was then separated by silica gel column chromatography to obtain compound 2C (0.5 g, 78.90%).

[0474] LC-MS (ESI): m / z = 377.9 [M+H] + .

[0475] Step 3: Compound 2C (0.1 g, 0.27 mmol), compound 1H (0.094 g, 0.27 mmol), potassium phosphate (0.11 g, 0.54 mmol), and XPhos Pd G2 (0.021 g, 0.027 mmol) were dissolved in DMF. After the addition was complete, nitrogen gas was introduced, and the mixture was heated to 100 °C for 3 h. After the reaction was complete, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was then subjected to reverse-phase medium-pressure reaction to prepare compound 2 (15 mg, 11.94%).

[0476] LC-MS (ESI): m / z = 473.2 [M+H] + .

[0477] 1H NMR(400MHz,DMSO-d6)δ10.89(s,1H),8.29(d,1H),7.91-7.54(m,1H),7.43-7.25(m,6H), 7.18-7.05(m,3H),5.28(s,2H),4.35-4.31(m,1H),2.88-2.51(m,2H),2.39-1.99(m,2H).

[0478] Example 3:

[0479] Step 1: Compound 1B (2.5 g, 14.53 mmol) was dissolved in DIPEA (10.09 mL, 61.03 mmol), and 3A (4.03 g, 15.98 mmol) was added at room temperature. The mixture was heated to 120 °C and stirred for 16 h. After the reaction was complete, PE:EA = 10:1 (50 mL) was added and the mixture was stirred. The mixture was filtered, the solid was discarded, and the filtrate was concentrated and separated by silica gel column chromatography to obtain compound 3B (2.0 g, yield 40.09%).

[0480] LC-MS (ESI): m / z = 343.0 [M+H] + .

[0481] Step 2: Dissolve 3B (1.5 g, 4.37 mmol) in 20 mL of 4 mol / L hydrochloric acid 1,4-dioxane solution and react at room temperature for 16 h. Then concentrate under reduced pressure, and beat the residue with 50 mL of ethyl acetate for 2 h. Filter and dry the resulting solid under reduced pressure to obtain crude compound 3C hydrochloride (1.22 g, 114.82%). This product was used directly in the next step of the reaction without further purification.

[0482] LC-MS (ESI): m / z = 243.1 [M+H] + .

[0483] Step 3: Compound 3C (500 mg, 2.06 mmol) was dissolved in 1,4-dioxane (10 mL), followed by the sequential addition of CNBr (1.09 g, 10.30 mmol) and triethylamine (4.17 g, 41.20 mmol). The mixture was heated to 110 °C and reacted for 16 h. After the reaction was complete, the mixture was cooled to room temperature, and 100 mL of water was added to the reaction solution. The solution was extracted with 100 mL of EA. The organic phase was washed sequentially with 10% citric acid (50 mL), water (50 mL), and saturated sodium chloride (100 mL). The organic phase was dried, filtered, and the filtrate was concentrated under reduced pressure. The residue was then separated by silica gel column chromatography to obtain compound 3D (120 mg, 21.76%).

[0484] LC-MS(ESI): m / z = 268.0 [M+H]+ .

[0485] Step 4: Compound 3D (120 mg, 0.45 mmol) was dissolved in 1,4-dioxane (10 mL) and water (1 mL), followed by the sequential addition of compound 1H (190 mg, 0.54 mmol), potassium phosphate (290 mg, 1.35 mmol), Ruphos Pd G3 (19 mg, 0.023 mmol), and X-phos (11 mg, 0.023 mmol). After the addition was complete, nitrogen gas was introduced, and the mixture was heated to 100 °C for 4 h. After the reaction was complete, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was then subjected to reverse-phase medium-pressure reaction to prepare compound 3 (28 mg, 15.23%).

[0486] LC-MS (ESI): m / z = 411.1 [M+H] + .

[0487] 1 H NMR(400MHz,DMSO-d6):10.87(s,1H),7.34-7.31(m,1H),7.24(d,2H),7.15(d,2H),6.64(d,2H),5.86-5.84(m,1H),4.33-4.29(m,1 H),3.15-3.08(m,4H),2.83(s,3H),2.82-2.72(m,1H),2.57-2.52(m,1H),2.37-2.26(m,1H),2.08-2.00(m,1H),1.88-1.81(m,2H).

[0488] Example 4:

[0489] Step 1: Sodium methoxide solution was prepared by slowly adding sodium metal (2.9 g, 125.3 mmol) to methanol (100 mL). After the reaction was complete, compound 4A (5.0 g, 27.9 mmol) was added, and the mixture was heated to 100 °C and reacted for 6 h. After the reaction was completed, the reaction solution was evaporated to dryness, and the residue was purified by column chromatography to obtain compound 4B (1.8 g, yield: 37%).

[0490] LC-MS (ESI): m / z = 176.0 [M+H] + .

[0491] Step 2: Compound 4B (1.0 g, 4.7 mmol) was dissolved in dichloromethane (20 mL), and then boron tribromide (3.9 g, 15.4 mmol) was added. The mixture was reacted at room temperature for 4 h. After the reaction was completed, the reaction solution was poured into water and extracted with dichloromethane. The organic phase was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 4C (0.2 g, yield: 22%).

[0492] LC-MS(ESI): m / z = 162.0 [M+H] + .

[0493] Step 3: Compound 4C (180.0 mg, 1.1 mmol) was dissolved in 1,4-dioxane (5 mL), and p-bromoiodobenzene (350.0 mg, 1.2 mmol), cuprous iodide (230.0 mg, 1.2 mmol), potassium phosphate (290.0 mg, 1.3 mmol), and N,N'-dimethylethylenediamine (110.0 mg, 1.2 mmol) were added sequentially. After the addition was complete, N2 was substituted, and the mixture was heated to 105 °C and reacted overnight. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 4D (130.0 mg, yield: 37%).

[0494] LC-MS (ESI): m / z = 316.0 [M+H] + .

[0495] Step 4: Compound 4D (120.0 mg, 0.38 mmol) was dissolved in 1,4-dioxane (6 mL) and water (0.6 mL). Then, 1H (160.0 mg, 0.46 mmol), X-phos (36.0 mg, 0.08 mmol), Ruphos Pd G3 (32.0 mg, 0.04 mmol), and potassium phosphate (81.0 mg, 0.38 mmol) were added sequentially. After the addition was complete, N2 was substituted, and the mixture was heated to 100 °C for 2 h. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain compound 4 (24.0 mg, yield: 14%).

[0496] LC-MS (ESI): m / z = 459.1 [M+H] + .

[0497] 1H NMR(400MHz,DMSO-d6)δ10.92(s,1H),7.73-7.68(m,1H),7.63-7.51(m,4H),7.48-7.35(m,4H),7.21-6.99(m,1H), 6.39-6.33(m,1H),4.41-4.33(m,1H),2.87-2.72(m,1H),2.61-2.52(m,1H),2.42-2.28(m,1H),2.13-2.02(m,1H).

[0498] Example 5:

[0499] Step 1: 1C (100 mg, 0.38 mmol) was dissolved in DMF (4 mL). Under a nitrogen atmosphere, Cs₂CO₃ (371.43 mg, 1.14 mmol) and 5A (144.51 mg, 0.76 mmol) were added in portions. The mixture was then heated to 60 °C and reacted for 16 h. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain compound 5B (20 mg, yield: 17.37%).

[0500] LC-MS (ESI): m / z = 304.1 [M+H] + .

[0501] Step 2: Compound 5B (20 mg, 0.066 mmol) was dissolved in 1,4-dioxane (4 mL) and water (0.4 mL), followed by the sequential addition of compound 1H (27.69 mg, 0.079 mmol), potassium phosphate (42.03 mg, 0.20 mmol), Ruphos Pd G3 (5.52 mg, 0.007 mmol), and X-phos (6.29 mg, 0.013 mmol). After the addition was complete, nitrogen was introduced, and the mixture was heated to 100 °C for 3 h. After the reaction was complete, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was then subjected to reverse-phase medium-pressure reaction to prepare compound 5 (4.7 mg, yield: 15.99%).

[0502] LC-MS (ESI): m / z = 447.1 [M+H] +

[0503] 1H NMR(400MHz,DMSO-d6)δ10.91(s,1H),8.29-8.23(m,2H),7.43-7.37(m,7H),4.40-4.31(m,1H),3.17-3.10(m,1H),2.86- 2.76(m,1H),2.59-2.51(m,1H),2.39-2.27(m,1H),2.12(s,3H),2.11-2.02(m,1H),0.91-0.80(m,2H),0.47-0.37(m,2H).

[0504] Example 6:

[0505] Step 1: Compound 6A (5 g, 51.48 mmol) was dissolved in DMF (50 mL), and Cs₂CO₃ (50.32 g, 154.44 mmol) and 1D (17.92 g, 77.22 mmol) were added at room temperature. The reaction was carried out at room temperature for 6 h. After the reaction was completed, the mixture was filtered, the filtrate was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain compound 6B (3.5 g, yield: 37.95%).

[0506] LC-MS (ESI): m / z = 180.1 [M+H] + .

[0507] Step 2: 6B (100 mg, 0.56 mmol) was dissolved in 1,4-dioxane (5 mL), and 6C (240.1 mg, 0.84 mmol), CuI (21.0 mg, 0.11 mmol), N,N'-dimethylethylenediamine (20.0 mg, 0.22 mmol), and potassium phosphate (240 mg, 1.12 mmol) were added. The mixture was then heated to 100 °C and reacted for 4 h. After the reaction was complete, the mixture was cooled to room temperature, poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was then separated by silica gel column chromatography to obtain compound 6D (23 mg, yield: 12.33%).

[0508] LC-MS (ESI): m / z = 334.0 [M+H] + .

[0509] Step 3: Using 6D (20 mg, 0.06 mmol) and 1H (20.98 mg, 0.060 mmol) as raw materials, compound 6 (15 mg, yield: 52.55%) was synthesized according to the method in step 3 of Example 1.

[0510] LC-MS (ESI): m / z = 477.2 [M+H] + .

[0511] 1 H NMR (400MHz, DMSO-d6): δ10.89(s,1H),7.65-7.61(m,1H),7.40-7.27(m,5H),7.26-7.10(m,2H),5.98-5.95(m,1H),4.67- 4.57(m,2H),4.37-4.29(m,1H),3.77(s,3H),2.84-2.73(m,1H),2.58-2.52(m,1H),2.39-2.26(m,1H),2.10-1.95(m,1H).

[0512] Example 7:

[0513] Step 1: Using 3C (400 mg, 1.65 mmol) and 1H (692.25 mg, 1.98 mmol) as raw materials, compound 7A (320 mg, 50.41%) was obtained by following the synthesis method in step 3 of Example 1.

[0514] LC-MS (ESI): m / z = 386.2 [M+H] + .

[0515] Step 2: 7A (30 mg, 0.078 mmol) was dissolved in dichloromethane (3 mL), and triethylamine (23.68 mg, 0.23 mmol) and phosgene (13.45 mg, 0.12 mmol) were added sequentially at 0 °C. The reaction was carried out at 0 °C for 2 h. After the reaction was completed, the solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was then separated by reverse-phase medium-pressure preparation to obtain compound 7 (2.85 mg, yield: 8.57%).

[0516] LC-MS (ESI): m / z = 428.1 [M+H] + .

[0517] 1 H NMR (400MHz, DMSO-d6): δ10.91(s,1H),7.43-7.28(m,7H),4.39-4.31(m,1H),3.70-3.60(m,2H),3.57- 3.50(m,2H),3.35(s,3H),2.86-2.74(m,1H),2.58-2.52(m,1H),2.39-2.27(m,1H),2.17-2.01(m,3H).

[0518] Example 8:

[0519] Step 1: Compound 8A (1 g, 4.37 mmol, synthesized according to patent WO2024151547), 8E (1.30 g, 4.37 mmol, synthesized according to patent WO2024151547), potassium phosphate (2.78 g, 13.11 mmol), and Pd(dppf)Cl2 (246 mg, 0.44 mmol) were dissolved in DMF (20 mL), and the mixture was heated to 90 °C and stirred for 16 h. After the reaction was completed, the reaction solution was poured into water (30 mL), extracted with ethyl acetate (30 mL * 2), washed with saturated brine (30 mL * 2), and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain compound 8B (550 mg, yield 39%).

[0520] LC-MS (ESI): m / z = 321.1 [M+H] + .

[0521] Step 2: Dissolve 8B (550 mg, 1.72 mmol) in toluene (15 mL), add Lawesson's reagent (1.39 g, 3.44 mmol) under a nitrogen atmosphere, and react at 100 °C for 1 h. After the reaction is complete, filter the reaction solution, concentrate the filtrate under reduced pressure, and separate the residue by silica gel column chromatography to obtain compound 8C (510 mg, yield 88%).

[0522] LC-MS (ESI): m / z = 337.0 [M+H] + .

[0523] Step 3: Compound 8C (100 mg, 0.29 mmol) was dissolved in tetrahydrofuran (20 mL), and sodium methoxide (3.2 mg, 0.06 mmol) was added under ice bath conditions. The mixture was stirred for 5 minutes, and then tert-butyl acrylate (38 mg, 0.29 mmol) was added dropwise. The mixture was slowly brought back to room temperature and reacted for 2 hours. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain 8D (70 mg, yield 51%).

[0524] LC-MS (ESI): m / z = 465.1 [M+H] + .

[0525] Step 4: Dissolve 8D (70 mg, 0.15 mmol) in acetic acid (10 mL), add concentrated sulfuric acid (1 mL) dropwise, and heat to 90 °C for 3 h. After the reaction is complete, slowly pour the reaction solution into ice water, extract with ethyl acetate, concentrate the organic phase under reduced pressure, and prepare compound 8 (5 mg, 8% yield) by reverse phase reaction.

[0526] LC-MS (ESI): m / z = 409.0 [M+H] + .

[0527] 1 H NMR (400MHz, CDCl3): δ8.02-7.92(s,1H),7.84-7.74(m,1H),7.72-7.63(m,1H),7.62-7.53(m,2H),7.47-7.33(m,4H),7.26-7 .21(m,1H),6.75-6.65(m,1H),4.40-4.27(m,1H),2.85-2.75(m,1H),2.40-2.28(m,1H),2.27-2.19(m,1H),2.05-1.07(m,1H).

[0528] Example 9:

[0529] Step 1: Using compound 9A (2.0 g, 15.98 mmol) as the starting material, compound 9B (2.4 g, yield: 53.69%) was synthesized according to the method in step 3 of Example 4.

[0530] LC-MS (ESI): m / z = 279.9 [M+H] + .

[0531] Step 2: Using compound 9B (0.5 g, 1.78 mmol) as the starting material, compound 9C (0.3 g, yield: 63.16%) was obtained by following the synthesis method in Step 2 of Example 4.

[0532] LC-MS (ESI): m / z = 265.9 [M+H] + .

[0533] Step 3: 9C (0.3 g, 1.13 mmol) was dissolved in DMF (4 mL), and Cs₂CO₃ (1.1 g, 3.39 mmol) and 5A (0.43 mg, 2.26 mmol) were added in portions under a nitrogen atmosphere. The mixture was then heated to 100 °C and reacted for 16 h. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was then separated by silica gel column chromatography to obtain compound 9D (0.16 g, yield: 46.35%).

[0534] LC-MS (ESI): m / z = 306.0 [M+H] + .

[0535] Step 4: Compound 9D (100.0 mg, 0.33 mmol) was dissolved in 1,4-dioxane (6 mL) and water (0.6 mL). Then, 1H (120 mg, 0.33 mmol), X-phos (36.0 mg, 0.08 mmol), Ruphos Pd G3 (32.0 mg, 0.04 mmol), and potassium phosphate (162.0 mg, 0.76 mmol) were added sequentially. After the addition was complete, N2 was substituted, and the mixture was heated to 100 °C for 2 h. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain compound 9 (10 mg, yield: 6.82%).

[0536] LC-MS (ESI): m / z = 449.1 [M+H] + .

[0537] 1 H NMR(400MHz,DMSO-d6)δ10.90(s,1H),7.56-7.54(m,2H),7.50-7.48(m,2H),7.44-7.37(m,3H),7.33-7.30(m,1H),7.22-7.1 7(m,1H),6.33-6.28(m,1H),4.39-4.35(m,1H),3.85-3.80(m,1H),2.80-2.60(m,2H),2.33-2.24(m,2H),0.80-0.70(m,4H).

[0538] Example 10:

[0539] Step 1: 4-Methoxybenzyl alcohol (1.75 g, 7.59 mmol) was dissolved in THF (20 mL). NaH (0.24 g, 6.07 mmol) was added in portions under a nitrogen atmosphere. After reacting at room temperature for 0.5 h, 10A (1.0 g, 5.06 mmol) was slowly added, and the temperature was then raised to 70 °C and the reaction continued for 16 h. After the reaction was completed, the reaction solution was slowly poured into ice water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain compound 10B (1.2 g, 79.21%).

[0540] Step 2: Dissolve 10B (1.0 g, 3.34 mmol) in methanol (10 mL), add 0.3 g of 10% palladium on carbon, hydrogenate and react at room temperature overnight, filter, concentrate the organic phase to obtain compound 10C (0.58 g, 96.91%).

[0541] LC-MS (ESI): m / z = 180.1 [M+H] + .

[0542] Step 3: Compound 10C (0.1 g, 0.56 mmol), 4-iodophenylboronic acid (0.15 g, 0.62 mmol), copper acetate (0.1 g, 0.56 mmol), and triethylamine (0.17 g, 1.68 mmol) were dissolved in 1,2-dichloroethane, oxygen was added, and the mixture was reacted at room temperature for 16 hours. After filtration, the organic phase was concentrated, and the residue was separated by silica gel column chromatography to obtain compound 10D (0.11 g, 51.70%).

[0543] LC-MS (ESI): m / z = 382.0 [M+H] + .

[0544] Step 4: Compound 10D (100.0 mg, 0.26 mmol) was dissolved in 1,4-dioxane (6 mL) and water (0.6 mL). Then, 1H (120 mg, 0.33 mmol), Xphos (36.0 mg, 0.08 mmol), Ruphos Pd G3 (32.0 mg, 0.04 mmol), and potassium phosphate (162.0 mg, 0.76 mmol) were added sequentially. After the addition was complete, N2 was substituted, and the mixture was heated to 100 °C for 2 h. After the reaction was complete, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain compound 10 (5 mg, yield: 4.00%).

[0545] LC-MS (ESI): m / z = 477.1 [M+H] + .

[0546] 1 H NMR(400MHz,DMSO-d6)δ10.91(s,1H),7.85-7.82(m,1H),7.75(d,1H),7.63-7.53(m,4H),7. 48-7.35(m,3H),6.42-6.38(m,1H),4.39-4.33(m,1H),2.84-2.58(m,2H),2.35-2.07(m,2H).

[0547] Example 11:

[0548] Step 1: Compound 11A (1.5 g, 7.14 mmol), p-diiodobenzene (2.83 g, 8.57 mmol), cuprous iodide (0.14 g, 0.71 mmol), and potassium carbonate (4.74 g, 34.27 mmol) were added to DMSO (20 mL), heated to 120 °C under nitrogen protection, stirred overnight, cooled, filtered, diluted with water, extracted with EA, washed the organic phase with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated the filtrate, and purified by silica gel column chromatography to obtain target compound 11B (0.2 g, yield 6.8%).

[0549] LC-MS(ESI): m / z = 413.0 [M+H] + .

[0550] Step 2: Add compound 11B (0.2g, 0.49mmol) to 5mL of ethyl hydrochloride (4M) solvent, stir at room temperature for 2 hours, and concentrate directly to dryness to obtain compound 11C, which can be used directly in the next step of the reaction.

[0551] LC-MS (ESI): m / z = 313.0 [M+H] + .

[0552] Step 3: Compound 11C (190 mg, 0.54 mmol) and triethylamine (160 mg, 1.62 mmol) were added to dichloromethane (10 mL), and cyclopropionyl chloride (85 mg, 0.81 mmol) was slowly added under ice bath conditions. The mixture was stirred for 2 hours, and the reaction was quenched by adding saturated ammonium chloride solution. The mixture was diluted with water, extracted with DCM, and the organic phases were combined. The mixture was dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography to obtain the target compound 11D (130 mg, 63%).

[0553] LC-MS (ESI): m / z = 381.0 [M+H] + .

[0554] Step 4: Compound 11D (130 mg, 0.34 mmol), compound 1H (120 mg, 0.34 mmol), potassium phosphate (220 mg, 1.02 mmol), and Pd(dppf)Cl2 (25 mg, 0.034 mmol) were added to DMF (10 mL), heated to 85 °C under nitrogen protection, stirred overnight, filtered, diluted with water, extracted with EA, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated the filtrate, and purified by HPLC to obtain the target compound 11 (30 mg, 18%).

[0555] LC-MS (ESI): m / z = 476.1 [M+H] + .

[0556] 1 H NMR (400MHz, DMSO-d6): δ10.08(s,1H),8.23(d,1H),7.58-7.47(m,5H),7.46-7.35(m,3H),7.32-7.15(m,1H),6.55(d,1H),4.43 -4.32(m,1H),2.87-2.74(m,1H),2.60-2.52(m,1H),2.42-2.28(m,1H),2.12-2.01(m,1H),1.74-1.67(m,1H),0.84-0.70(m,4H).

[0557] Example 12:

[0558] Step 1: Compound 12A (500 mg, 1.61 mmol), 3-methyleneazacyclobutane hydrochloride (340 mg, 3.22 mmol), sodium tert-butoxide (460 mg, 4.83 mmol), Xphos (77 mg, 0.16 mmol), and Pd2(dba)3 (150 mg, 0.16 mmol) were added to toluene (20 mL), heated to 100 °C under nitrogen protection, stirred overnight, cooled, filtered, diluted with water, extracted with EA, collected the organic phase, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated the filtrate, and purified by silica gel column chromatography to obtain target compound 12B (60 mg, yield 15%).

[0559] LC-MS (ESI): m / z = 253.1 [M+H] + .

[0560] Step 2: Compound 12B (60 mg, 0.49 mmol) was added to trifluoroacetic acid (20 mL) solvent, heated to 45 °C and stirred overnight. The reaction of the starting material was monitored by LCMS until complete. The mixture was directly concentrated to dryness to obtain the target compound 12C. This crude product was directly used in the next step of the reaction.

[0561] LC-MS (ESI): m / z = 163.1 [M+H] + .

[0562] Step 3: Compound 12C (60 mg, 0.37 mmol), 4-bromophenylboronic acid (89 mg, 0.44 mmol), copper acetate (67 mg, 0.37 mmol), and triethylamine (110 mg, 1.11 mmol) were dissolved in 1,2-dichloroethane (10 mL), oxygen was added, and the mixture was reacted at room temperature for 16 hours. The mixture was filtered, and the residue after concentration was separated by silica gel column chromatography to obtain compound 12D (50 mg, 43%).

[0563] LC-MS (ESI): m / z = 317.0 [M+H] + .

[0564] Step 4: Compound 12D (50 mg, 0.16 mmol), compound 1H (56 mg, 0.16 mmol), potassium phosphate (100 mg, 0.48 mmol) and Pd(dppf)Cl2 (12 mg, 0.016 mmol) were added to DMF (8 mL), heated to 85 °C under nitrogen protection and stirred overnight. The mixture was filtered, diluted with water, extracted with EA, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by HPLC to obtain the target compound 12 (5 mg, 7%).

[0565] LC-MS (ESI): m / z = 460.1 [M+H] + .

[0566] 1 H NMR (400MHz, DMSO-d6): δ10.91(s,1H),7.55(d,1H),7.52-7.48(m,2H),7.46-7.37(m,4H),7.36-7.33(m,1H),5.81-5.75(m,1H),5. 16-5.08(m,3H),4.60-4.50(m,4H),4.40-4.32(m,1H),2.85-2.75(m,1H),2.60-2.55(m,1H),2.38-2.32(m,1H),2.12-2.02(m,1H).

[0567] Example 13:

[0568] Step 1: 13A (1.00 g, 4.18 mmol) was dissolved in 1,4-dioxane (20 mL), followed by the sequential addition of dimethyl sulfinamide (0.59 g, 6.26 mmol), cesium carbonate (2.04 g, 6.26 mmol), and XantPhos (0.48 g, 0.84 mmol). Under nitrogen protection, Pd₂(dba)₃ (0.36 g, 0.63 mmol) was added. After the addition was complete, the reaction mixture was heated to 100 °C and reacted for 16 h. After the reaction was complete, the reaction mixture was filtered to obtain the filtrate, which was concentrated under reduced pressure and then separated by silica gel column chromatography to obtain compound 13B (500 mg, 58.49%).

[0569] LC-MS (ESI): m / z = 205.1 [M+H] + .

[0570] Step 2: Dissolve 13B (500 mg, 2.44 mmol) in 12N hydrochloric acid (15 mL), stir the reaction solution overnight at 50 °C, and concentrate under reduced pressure to obtain crude compound 13C (520 mg), which is directly used in the next step of the reaction.

[0571] LC-MS (ESI): m / z = 187.2 [M+H] + .

[0572] Step 3: The crude compound 13C (520 mg) was dissolved in 1,2-dichloroethane (20 mL), and 4-bromophenylboronic acid (650 mg, 3.22 mmol), copper acetate (490 mg, 2.68 mmol), and triethylamine (815 mg, 8.05 mmol) were added sequentially. After the addition was complete, the reaction solution was reacted overnight at room temperature under oxygen. The reaction solution was filtered to obtain the filtrate, which was concentrated under reduced pressure and separated by silica gel column chromatography to obtain compound 13D (500 mg, 54.58%).

[0573] LC-MS (ESI): m / z = 341.1 [M+H] + .

[0574] Step 4: Compound 13D (200 mg, 0.59 mmol) was dissolved in DMF (10 mL), followed by the sequential addition of 1H (225 mg, 0.64 mmol), Pd(dppf)Cl2 (65 mg, 0.09 mmol), and potassium phosphate (375 mg, 1.76 mmol). After the addition was complete, the mixture was placed under displacement protection and heated to 100 °C for 4 h. After the reaction was complete, the reaction solution was poured into water, extracted three times with dichloromethane, and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. This residue was purified by prep.HPLC to obtain the target compound 13 (30 mg, yield: 10.58%).

[0575] LC-MS (ESI): m / z = 484.2 [M+H] + .

[0576] 1 H NMR(400MHz,DMSO-d6)δ10.91(s,1H),7.53-7.35(m,8H),5.99-5.97(m,1H),5.86(s,1H),4.38-4.36(m,1H), 3.38-3.33(m,3H),2.84-2.78(m,1H),2.58-2.54(m,1H),2.51(s,3H),2.37-2.34(m,1H),2.10-2.05(m,1H).

[0577] Example 14:

[0578] Step 1: Compound 14A (210 mg, 0.55 mmol, synthesized according to patent EP3778576) was dissolved in DCM (10 mL), and 3-methyleneazacyclobutane (57 mg, 0.82 mmol) and DIPEA (213 mg, 1.65 mmol) were added at room temperature. The mixture was stirred at room temperature for 2 h. After the reaction was completed by TLC monitoring, the mixture was washed twice with water (5 mL x 2), the organic phase was dried and concentrated, and compound 14B (130 mg, yield 75.7%) was obtained by silica gel column chromatography.

[0579] LC-MS (ESI): m / z = 315.0 [M+H] + .

[0580] Step 2: Compound 14B (130 mg, 0.41 mmol) was dissolved in 1,4-dioxane (10 mL) and water (1 mL), followed by the sequential addition of compound 1H (217 mg, 0.62 mmol), potassium carbonate (171 mg, 1.24 mmol), and PdCl2dppf (30 mg, 0.041 mmol). After the addition was complete, nitrogen gas was introduced, and the mixture was heated to 80 °C for 4 h. After the reaction was completed as monitored by LCMS, it was cooled to room temperature. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was then analyzed by HPLC to obtain compound 14 (12 mg, 7.1%).

[0581] LC-MS (ESI): m / z = 410.2 [M+H] + .

[0582] 1 H NMR (400MHz, DMSO-d6): δ8.68(s,1H),7.61-7.55(m,2H),7.40-7.26(m,5H),5.09-5.05(m,2H),4.55( t,4H),4.36-4.30(m,1H),2.85-2.65(m,1H),2.58-2.54(m,1H),2.39-2.26(m,1H),2.09-2.01(m,1H).

[0583] Example 15:

[0584] Step 1: Compound 6A (3 g, 30.89 mmol) was dissolved in dioxane (50 mL), and K3PO4 (19.67 g, 92.67 mmol), p-bromoiodobenzene (8.74 g, 30.89 mmol), and Xantphos Pd G3 (3.19 g, 3.09 mmol) were added at room temperature. Under nitrogen protection, the mixture was heated to 100 °C for 6 h. After the reaction was complete, the mixture was filtered, and the filtrate was poured into water and extracted with ethyl acetate. The organic phase was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography to obtain compound 15A (5.2 g, yield: 66.77%).

[0585] LC-MS (ESI): m / z = 252.0 [M+H] + .

[0586] Step 2: 15A (500 mg, 1.98 mmol) was dissolved in DMF (5 mL), and sodium hydride (240 mg, 5.94 mmol) was added in portions under nitrogen atmosphere. The mixture was then heated to 60 °C and reacted for 0.5 h. Cyclopropyl trifluoromethanesulfonate (564.7 mg, 2.97 mmol) was added, and the reaction was continued at 60 °C for 4 h. After the reaction was complete, the mixture was cooled to room temperature, poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain compound 15B (160 mg, yield: 27.61%).

[0587] LC-MS(ESI): m / z = 292.0 [M+H] + .

[0588] Step 3: Using 15B (160 mg, 0.55 mmol) and 1H (193 mg, 0.55 mmol) as raw materials, compound 15 (60 mg, yield: 25.19%) was obtained by following the synthesis method in Step 3 of Example 1.

[0589] LC-MS (ESI): m / z = 435.1 [M+H] + .

[0590] 1 H NMR(400MHz,DMSO-d6)δ10.89(s,1H),7.67-7.64(m,1H),7.38-7.32(m,1H),7.32-7.22(m,4H),7.19-7.12(m,2H),6.08-6.03(m,1H),4.36- 4.28(m,1H),3.79(s,3H),2.85-2.73(m,2H),2.58-2.51(m,1H),2.38- 2.24(m,1H),2.10-1.98(m,1H),0.94-0.82(m,2H),0.60-0.49(m,2H).

[0591] Example 16:

[0592] Step 1: Dissolve 1C (100 mg, 0.38 mmol) in DMF (4 mL), add NaH (46.0 mg, 1.14 mmol) in portions under a nitrogen atmosphere, then heat to 60 °C and react for 0.5 h. After cooling to room temperature, add allyl bromide (46.0 mg, 0.38 mmol) and continue the reaction at room temperature for 4 h. After the reaction is complete, pour the reaction solution into water, extract with ethyl acetate, concentrate the organic phase under reduced pressure, and separate the residue by silica gel column chromatography to obtain compound 16A (86 mg, yield: 74.67%).

[0593] LC-MS (ESI): m / z = 304.1 [M+H] + .

[0594] Step 2: Using 16A (50 mg, 0.16 mmol) and 1H (72.7 mg, 0.21 mmol) as raw materials, compound 16 (15 mg, yield: 28.59%) was synthesized according to the method in step 3 of Example 1.

[0595] LC-MS (ESI): m / z = 447.1 [M+H] +

[0596] 1 H NMR(400MHz,DMSO-d6)δ10.90(s,1H),8.30-8.23(m,2H),7.42-7.36(m,7H),6.04-5.90(m,1H),5.17-5.06(m,2H),4.68- 4.59(m,2H),4.39-4.30(m,1H),2.86-2.72(m,1H),2.59-2.51(m,1H),2.40-2.27(m,1H),2.12(s,3H),2.12-2.01(m,1H).

[0597] Example 17:

[0598] Step 1: 15A (500 mg, 1.98 mmol) was dissolved in DMF (5 mL), and NaH (237.6 mg, 5.94 mmol) was added in portions under a nitrogen atmosphere. The mixture was then heated to 60 °C and reacted for 0.5 h. After cooling to room temperature, bromomethylcyclopropane (400.9 mg, 2.97 mmol) was added, and the reaction was continued at room temperature for 4 h. After the reaction was completed, the reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain compound 17A (260 mg, yield: 42.81%).

[0599] Step 2: Using 17A (200 mg, 0.65 mmol) and 1H (272.7 mg, 0.78 mmol) as raw materials, compound 17 (93 mg, yield: 31.72%) was synthesized according to the method in step 3 of Example 1.

[0600] LC-MS (ESI): m / z = 449.2 [M+H] +

[0601] 1 H NMR(400MHz,DMSO-d6)δ10.88(s,1H),7.61-7.58(m,1H),7.39-7.21(m,5H ),7.11-7.01(m,2H),5.98-5.94(m,1H),4.38-4.28(m,1H),3.76(s,3H),3. 68-3.60(m,2H),2.84-2.71(m,1H),2.59-2.52(m.1H),2.39-2.24(m,1H),2 .14-1.94(m,1H),1.24-1.06(m,1H),0.47-0.32(m,2H),0.27-0.20(m,2H).

[0602] Example 18:

[0603] Step 1: Compound 18A (2.0 g, 9.51 mmol), p-bromophenylboronic acid (2.86 g, 14.27 mmol), copper acetate (1.73 g, 9.51 mmol), and triethylamine (2.89 g, 28.53 mmol) were added to dichloromethane (30 mL), stirred overnight under an oxygen atmosphere, filtered, diluted with water, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated the filtrate, and purified by silica gel column chromatography to obtain the target compound 18B (1.5 g, yield 43.17%).

[0604] LC-MS(ESI):m / z=309.0[M-56+H] + .

[0605] Step 2: Add compound 18B (1.5g, 4.11mmol) to 20mL of ethyl acetate hydrochloride (4M) solvent, stir at room temperature for 2 hours, and the starting material disappears as detected by TLC. Concentrate directly to dryness to obtain compound 18C, which can be used directly in the next reaction.

[0606] Step 3: Compound 18C (1.5 g, 5.66 mmol) and triethylamine (1.72 g, 16.98 mmol) were added to dichloromethane (20 mL), and cyclopropionyl chloride (0.89 g, 8.49 mmol) was slowly added under ice bath conditions. The mixture was stirred for 2 hours, and the reaction was quenched by adding saturated ammonium chloride solution. The mixture was diluted with water, extracted with DCM, and the organic phases were combined. The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography to obtain the target compound 18D (1 g, 53%).

[0607] LC-MS (ESI): m / z = 333.0 [M+H] + .

[0608] Step 4: Compound 18D (300 mg, 0.90 mmol), compound 1H (470 mg, 1.35 mmol), potassium phosphate (570 mg, 2.70 mmol), and Pd(dppf)Cl2 (66 mg, 0.09 mmol) were added to 1,4-dioxane (10 mL), heated to 90 °C under nitrogen protection, stirred overnight, filtered, diluted with water, extracted twice with ethyl acetate (10 ...

Claims

1. A compound of Formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: ###00001### (I). wherein Ring C is selected from a bond, a 3-15 membered carbocyclic ring, or a 4-15 membered heterocyclic ring, when Ring C is selected from a bond, R C is directly connected to L2; Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy group, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 (halogenated alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-8 membered heterocycloalkyl), -Se-C 3-8 Cycloalkyl, -C(=O)-C 3-8 Cycloalkyl, -C(=O)-(4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -C(=O)NR y -C 3-8 Cycloalkyl, -NHC(=O)- (4-8 membered heterocyclic alkyl), -C(=O)NH- (4-8 membered heterocyclic alkyl), -NHSO2- (4-8 membered heterocyclic alkyl), -SO2-C 3-8 cycloalkyl, -SO2NH-C 3-8 Cycloalkyl, -SO2- (4-8 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 alkyl-(4-8 membered heterocycloalkyl), -N=S(=O)(C 1-6 alkyl)2, -OC(=O)-(4-8 membered heterocycloalkyl), -O-(5-6 membered heteroaryl), -C(=O)-(5-6 membered heteroaryl), -C(=O)O-C 3-8 cycloalkyl, -SO2-NH-C(=O)O-C 1-3 alkyl, -C(=O)NH-SO2-C 3-8 cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), -C(=O)NRaRb, C 2-6 alkenyl, C 2-6 alkynyl, -C 1-3 alkyl-NRy-C 3-8 cycloalkyl, -C 1-3 alkyl-NH-C 3-8 cycloalkyl, 5-6 membered heteroaryl, -C(=S)NR y -C 3-8 cycloalkyl, -C(=S)NH-C 3-8 cycloalkyl, =N-C 3-8 cycloalkyl, -NH-(4-8 membered heterocycloalkyl), -NR y -(4-8 membered heterocycloalkyl), C 1-6 haloalkyl, -NH-(5-6 membered heteroaryl), -NR y -(5-6 membered heteroaryl), said alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH are optionally further substituted with 1-5 R x ; R y selected from D, C 1-4 alkyl, C 1-4 alkoxy, deuterated C 1-4 alkyl, halogenated C 1-4 alkyl, C 3-6 cycloalkyl; Ra, Rb are each independently selected from the group consisting of hydrogen, deuterium, cyano, C 1-6 alkyl, C 1-6 alkoxy, said alkyl, alkoxy optionally further substituted with 1-5 R x groups; C y1 、C y2 、C y3 each independently selected from 3-8 membered cycloalkyl, 4-10 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-8 membered aryl, said cycloalkyl, heterocycloalkyl, aryl or heteroaryl optionally further substituted with 1-5 R x . L2is selected from the group consisting of a bond, C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, -C 1-6 alkylene-C(=0)-, -0-C 1-6 alkylene-, -C 1-6 alkylene-O-, -NR L2 -, -NH-C(=0)-, -NH-C(=0)0-C 1-6 alkylene-, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, -0-, -Se-, -NR y -C(=0)-, -N(C 1-3 alkyl)-SO2-, -NH-, -NR L2 -SO2-, -NR y -SO2-, -N=4-8 membered heterocycloalkyl-, -N(C 1-3 alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 alkynyl)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 heterocycloalkyl)-, -N(CO-(5-6 membered heteroaryl))-, 3-6 cycloalkyl-(5-6 membered heteroaryl))-, 2-6 alkenyl)-, -N(C 2-6 alkynyl)-, -N(C 1-3 alkyl)-, -N(SO2-C 3-8 cycloalkyl)-, -NR y -C(=0)0-, -NR y -C(=0)NH-, -OC(=0)-, -C(=0)-NR y -, -OC(=0)-NR y -, -SO2-NR y -, said alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, -NH being optionally substituted with 1-5 R x ; R L2 selected from deuterium, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuteroalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 deuteroalkoxy, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-6 alkyl, -NR y -SO2C 1-6 alkyl, -NR y -CN, -SO2-C 3-6 cycloalkyl, -SO2-C 1-6 alkyl, -SO2-(4-6 membered heterocycloalkyl), -SO2-(5-6 membered heteroaryl), said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl being optionally further substituted with 1-5 R x ; each R x is independently selected from deuterium, halogen, hydroxyl, cyano, amino, nitro, =0, =S, =NH, -NHCOC 1-3 alkyl, -N(C 1-3 alkyl)2, -NH(C 1-3 alkyl), -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C 1-3 alkyl), =C(C 1-3 haloalkyl), =CF(C 1-3 alkyl), =C(C 1-3 haloalkyl), =C(C 1-3 alkyl)2, =C(C 1-3 alkyl)(C 1-3 haloalkyl), =C 4-6 cycloalkyl, =(4-6 membered heterocycloalkyl), C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuteroalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 deuteroalkoxy, C 1-6 alkylamino, C 3-8 cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8 cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), said alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, NH being optionally further substituted with 1-5 groups selected from deuterium, halogen, hydroxyl, cyano, amino, =0, -SF5, -SCF3, =CH2, =CF2, =CH(C 1-3 alkyl), =C(C 1-3 alkyl)2, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuteroalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 deuteroalkoxy, -SO2C 1-3 alkyl or -COC 1-3 alkyl; t is an integer from 0 to 5; with the proviso that the compound of formula (I) meets the following conditions: 1) L2is not selected from -CH2-; or 2) when L2is selected from a bond, C 1-6 alkylene, -C 1-6 alkylene-C(=O)-, -O-C 1-6 alkylene-, -C 1-6 alkylene-O-, -NH-C(=O)-, t is not 0 and at least one R C is not selected from =O and C 1-6 alkyl.

2. The compound of formula (I) as claimed in claim 1, stereoisomers or pharmaceutically acceptable salts thereof, wherein, Formula (I) is further illustrated by Formula (II), Formula (III), Formula (VI), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X): selected from the group consisting of or preferably selected from the group consisting of R C1 Selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-3 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-6 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-8 membered cycloalkyl, -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-7 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl)2, -C y1 -C y2 -C y3 -OC(=O)-(4-8-membered heterocyclic alkyl), -O-(5-6-membered heteroaryl), -C(=O)-(5-6-membered heteroaryl), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 Alkyl group, -C(=O)NH-SO2-C 3-8 Cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 Cycloalkanes, -C 1-3 Alkyl-NRy-C 3-8 Cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), -C(=O)-C 3-8 cycloalkyl, -C 1-3 Alkyl-NH-C 3-8 cycloalkyl, 5-6 membered heteroaryl, -C(=S)NH-C 3-8 cycloalkyl, =N-C 3-8 cycloalkyl, -NH-(4-8 membered heterocycloalkyl), -NR y -(4-8 membered heterocycloalkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6 membered heteroaryl), -NH-C 3-8 cycloalkyl, said alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH x are optionally further substituted by 1-5 R Ra, Rb are each independently selected from the group consisting of hydrogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, said alkyl, alkoxy groups are optionally further substituted by 1 to 5 R x groups; L 21 selected from C 2-6 alkylene, -C 1-6 alkylene-C(=O)-, -O-C 1-6 alkylene-, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -SO2-, -NR L2 -, -NH-C(=O)O-C 1-6 alkylene-, 3-6 membered cycloalkyl, -NR y -C(=O)-, -NH-C(=O)-, -NR y -C(=O)O-, -NR y -C(=O)NH-, -C(=O)-NR y -, -SO2-NR y -, -OC(=O)-NR y -, -OC(=O)-; t is an integer from 0, 1, 2, 3, 4.

3. The compound, stereoisomer, or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein, Ring C is selected from a bond, 3-6 membered cycloalkyl, 4-8 membered heterocycloalkyl, 7-11 bicyclic heterocyclyl, 7-12 tricyclic heterocyclyl, 5-6 membered heteroaryl, 6-8 membered aryl; Each R C Each is independently selected from =O, =S, =Se, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkynyl-cyano, C 1-6 Haloalkoxy groups, -S(=O)(=NH)-C 1-6 Alkyl, -N=S(=O)(C 1-3 Alkyl)2、-P(=O)(C 1-3 Alkyl group 2, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, -OC 3-8 Cycloalkyl, -O- (4-6 membered heterocycloalkyl), -C(=O)- (4-8 membered heterocycloalkyl), -NHC(=O)-C 3-8 Cycloalkyl, -C(=O)NH-C 3-8 Cycloalkyl, -NHSO2- (4-8 membered heterocycloalkyl), -SO2-C 3-6 Cycloalkyl, -SO2- (4-6 membered heterocycloalkyl), 4-8 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y3 -SO2C 1-3 Alkyl, halogen, -P (=O) (OC) 1-3 Alkyl)2、-NHC 3-8 cycloalkyl, -NH-SO2-C 1-3 Alkyl, -C 1-3 Alkyl-C 3-8 cycloalkyl, -C 1-3 Alkyl-OC 3-8 cycloalkyl, -C 1-3 Alkyl-(4-8 membered heterocyclic alkyl), -C 1-3 Alkyl-(5-6-membered heteroaryl), -Se-C 3-6 Cycloalkyl, -C(=O)NR y -C 3-8 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NR y C 3-8 Cycloalkyl, -N=S(=O)(C 1-6 Alkyl group 2, -OC(=O)- (4-8 membered heterocyclic alkyl group), -O- (5-6 membered heteroaryl group), -C(=O)- (5-6 membered heteroaryl group), -C(=O)OC 3-8 Cycloalkyl, -SO2-NH-C(=O)OC 1-3 alkyl, -C(=O)NH-SO2-C 3-8 cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 cycloalkyl, -C 1-3 alkyl-NRy-C 3-8 cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), 5-6 membered heteroaryl, -C(=O)-C 3-8 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuteroalkyl, C 1-6 haloalkyl, -NH-(5-6 membered heteroaryl), -NR y -(5-6 membered heteroaryl), said alkoxy, alkyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl optionally further substituted with 1-5 R x substituents; R C1 selected from =S, =NH, NH2, -SF5, -SCF3, -NHSO2NH2, C 2-6 alkynyl-cyano, C 1-6 haloalkoxy, -S(=O)(=NH)-C 1-3 alkyl, -N=S(=O)(C 1-3 alkyl)2, -P(=O)(C 1-3 alkyl)2, =CH2, =CF2, =CH(C 1-3 alkyl), =C(C 1-3 alkyl)2, -O-C 3-6 cycloalkyl, -O-(4-6 membered heterocycloalkyl), -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl, -NHSO2-(4-6 membered heterocycloalkyl), -SO2-C 3-6 cycloalkyl, -SO2-(4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -SO2NH-C 3-6 cycloalkyl, 3-8 membered cycloalkyl, -C 1-3 alkyl-(5-6 membered heteroaryl), -Se-C 3-7 cycloalkyl, C(=O)NR y -C 3-8 cycloalkyl, -NR y C 3-8 cycloalkyl, -N=S(=O)(C 1-6 alkyl)2, -C y1 -C y2 -C y2 -C y3 , -OC(=O)-(4-8 membered heterocycloalkyl), -O-(5-6 membered heteroaryl), -C(=O)-(5-6 membered heteroaryl), -C(=O)O-C 3-8 cycloalkyl, -SO2-NH-C(=O)O-C 1-3 alkyl, -C(=O)NH-SO2-C 3-8 cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-8 cycloalkyl, -C 2-6 alkenyl-C 3-8 cycloalkyl, -C 1-3 alkyl-NRy-C 3-8 cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), 5-6 membered heteroaryl, -C(=O)-C 3-8 cycloalkyl, -C 1-3 alkyl-NH-C 3-8 cycloalkyl, -C(=S)NH-C 3-8 cycloalkyl, -NH-(4-6 membered heterocycloalkyl), -NR y -(4-6 membered heterocycloalkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6 membered heteroaryl), said alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH optionally further substituted with 1-5 R x substituents; L2is selected from the group consisting of a bond, C 1-4 alkylene, C 2-4 alkenylene, C 2-4 alkynylene, -C 1-4 alkylene-C(=O)-, -O-C 1-4 alkylene-, -C 1-4 alkylene-O-, -NR L2 -, -NH-C(=O)-, -NH-C(=O)O-C 1-4 alkylene-, 3-5 membered cycloalkyl, 4-6 membered heterocycloalkyl, -O-, -Se-, -NR y -C(=O)-, -N(C 1-3 alkyl)-SO2-, -NH-, -NR L2 -SO2-, -N=4-8 membered heterocycloalkyl-, -N(C 1-3 alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 alkynyl)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-8 cycloalkyl)-, -N(CO-C 4-6 heterocycloalkyl)-, -N(CO-(5-6 membered heteroaryl))-, 3-6 cycloalkyl-(5-6 membered heteroaryl))-, 2-6 alkenyl)-, -N(C 2-6 alkynyl)-, -N(C 1-3 alkyl)-, -N(SO2-C 3-8 cycloalkyl)-, -NR y -C(=O)O-, -NR y -C(=O)NH- or -OC(=O)-, said alkylene, alkenylene, alkynylene, heteroaryl, -NH, cycloalkyl being optionally substituted with 1-5 R x ; R L2 selected from deuterium, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 deuterated alkyl, C 1-4 halogenated alkyl, C 1-4 alkoxy, C 1-4 halogenated alkoxy, C 1-4 deuterated alkoxy, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, -NR y -C(=O)C 1-2 alkyl, -NR L2 -SO2C 1-2 alkyl, -NR L2 -CN, -SO2-C 1-2 alkyl, -SO2-C 3-6 cycloalkyl, -SO2-(4-6 membered heterocycloalkyl), -SO2-(5-6 membered heteroaryl), said alkyl, alkoxy, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, alkenyl, alkynyl being optionally further substituted with 1-5 R x ; Each R x Each is independently selected from deuterium, halogen, hydroxyl, cyano, =O, =S, =NH, -NHCOC 1-3 Alkyl, -N(C) 1-3 alkyl)2、-NH(C 1-3 Alkyl groups, -SF5, -SCF3, =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy, C 3-8 Cycloalkyl, 4-8 membered heterocycloalkyl, 6-8 membered aryl, 5-10 membered heteroaryl, -NH(C 3-8 cycloalkyl) or -NH-O-(C 3-8 cycloalkyl), wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl, aryl or heteroaryl, NH optionally further selected from 1-3 radicals selected from deuterium, halogen, hydroxyl, cyano, amino, =O, =CH2, =CF2, =CHF, =CH(C 1-3 Alkyl), =C(C) 1-3 Alkyl)2, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Deuterated alkoxy group, -SO2C 1-3 Alkyl or -COC 1-3 Alkyl group substitution; R y selected from D, C 1-2 alkyl, C 1-2 alkoxy, deuterated C 1-2 alkyl, halogenated C 1-2 alkyl, C 3-6 cycloalkyl.

4. The compound, stereoisomer, or pharmaceutically acceptable salt thereof according to claim 1, wherein, Ring C is selected from the group consisting of cyclobutenyl, each R is independently selected from =0, =S, =Se, =NH, -SF5, -SCF3, -NHSO2NH2, CN, C C alkyl, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkynyl-cyano, C 1-4 haloalkoxy, -S(=0)(=NH)-C 1-4 alkyl, -N=S(=0)(C 1-3 alkyl)2, -P(=0)(C 1-3 alkyl)2, =CH2, =CF2, -0-C 3-6 cycloalkyl, -0-(4-6 membered heterocycloalkyl), -C(=0)-(4-6 membered heterocycloalkyl), -NHC(=0)-C 3-6 cycloalkyl, -C(=0)NH-C 3-6 cycloalkyl, -NHSO2-(4-6 membered heterocycloalkyl), -SO2-C 3-6 cycloalkyl, -SO2-(4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, 3-6 membered cycloalkyl, -C y1 -C y2 -C y2 -C y3 , -SO2C 1-3 alkyl, halo, -P(=0)(OC 1-3 alkyl)2, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -NH-SO2-C 1-3 alkyl, -C 1-3 alkyl-C 3-8 cycloalkyl, -C 1-3 alkyl-O-C 3-8 cycloalkyl, -C 1-3 alkyl-(4-8 membered heterocycloalkyl), -SO2NH-C 3-6 cycloalkyl, -Se-C 3-6 cycloalkyl, -C(=0)NR y -C 3-6 cycloalkyl, -C 1-3 alkyl-(5-6 membered heteroaryl), -N=S(=0)(C 1-6 alkyl)2, -OC(=0)-(4-8 membered heterocycloalkyl), -0-(5-6 membered heteroaryl), -C(=0)-(5-6 membered heteroaryl), -C(=0)0-C 3-8 cycloalkyl, -SO2-NH-C(=0)0-C 1-3 alkyl, -C(=0)NH-SO2-C 3-8 cycloalkyl, -C(=0)NH-(5-6 membered heteroaryl), 5-6 membered heteroaryl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 deuteroalkyl, C 1-4 haloalkyl, the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH2, NH, alkenyl groups being optionally further substituted by 1-5 R x substituents; R C1 selected from =S, =NH, -SF5, -SCF3, -NHSO2NH2, C 2-4 alkynyl-cyano, C 1-4 haloalkoxy, -S(=O)(=NH)-C 1-3 alkyl, -N=S(=O)(C 1-3 alkyl)2, -P(=O)(C 1-3 alkyl)2, =CH2, =CF2, -O-C 3-6 cycloalkyl, -O-(4-6 membered heterocycloalkyl), -C(=O)-(4-6 membered heterocycloalkyl), -NHC(=O)-C 3-6 cycloalkyl, -C(=O)NH-C 3-6 cycloalkyl, -NHSO2-(4-6 membered heterocycloalkyl), -SO2-C 3-6 cycloalkyl, -SO2-(4-6 membered heterocycloalkyl), 4-6 membered heterocycloalkyl, -Se-C 3-6 cycloalkyl, -C(=O)NR y -C 3-6 cycloalkyl, -SO2NH-C 3-8 cycloalkyl, -NHC 3-6 cycloalkyl, -NR y C 3-6 cycloalkyl, -C 1-3 alkyl-(5-6 membered heteroaryl), -C 1-3 alkyl-O-C 3-6 cycloalkyl, -C 1-3 alkyl-C 3-8 cycloalkyl, -C 1-3 alkyl-(4-8 membered heterocycloalkyl), -N=S(=O)(C 1-6 alkyl)2, -C y1 -C y2 -C y2 -C y3 , -OC(=O)-(4-8 membered heterocycloalkyl), -O-(5-6 membered heteroaryl), -C(=O)-(5-6 membered heteroaryl), -C(=O)O-C 3-8 cycloalkyl, -SO2-NH-C(=O)O-C 1-3 alkyl, -C(=O)NH-SO2-C 3-8 cycloalkyl, -C(=O)NRaRb, -C(=S)NR y -C 3-6 cycloalkyl, -C 2-4 alkenyl-C 3-6 cycloalkyl, -CH2-NRy-C 3-6 cycloalkyl, -C(=O)NH-(5-6 membered heteroaryl), 5-6 membered heteroaryl, -C(=O)-C 3-6 cycloalkyl, =NC 3-6 cycloalkyl, -CH2-NH-C 3-6 cycloalkyl, -C(=S)NH-C 3-6 Cycloalkyl, -NH- (4-6 membered heterocycloalkyl), -NR y -(4-6 membered heterocyclic alkyl), -NH-(5-6 membered heteroaryl), -NR y -(5-6 heteroaryl groups), -C(=O)NR y -C 3-8 Cycloalkyl, wherein the alkyl, alkoxy, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, NH, CH2 optionally are further surrounded by 1-5 R x Replaced, or R C1 Selected from 1-2 of the following: =CH2, =CF2, =CHF, =CH(C) 1-3 Alkyl), =C(C) 1-3 Alkyl)2、=CH(C 1-3 Halogenated alkyl), =CF(C) 1-3 Alkyl), =C(C) 1-3 3-8 membered cycloalkyl groups substituted with a haloalkyl group; Preferred R C1 Selected from -OCHF2, -OCF3, -SCF3, -SCF3, -NHSO2NH2, -S(=O)(=NH)-CH3, -N=S(=O)(CH3)2, -P(=O)(CH3)2, -C(=O)NH-CH2-CN, -C(=O)NH-CH(CH3)-CF3, -S(=O)2-NH-C(=O)O-CH3, -C(=O)NH-CN, L2is selected from the group consisting of a bond, C 2-4 alkylene, -C(O)-, -C 1-2 alkylene-C(O)-, -O-C 1-2 alkylene-, -N(C 1-4 alkoxy)-, -N(C 3-6 cycloalkyl)-, -N(C 1-4 haloalkyl)-, -N(C 2-4 alkenyl)-, -N(C 2-4 alkynyl)-, -NR y C(O)-, -NHC(O)O-C 1-2 alkylene, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, azolidinyl, piperidinyl, -O-, -Se-, -N(C 1-2 alkyl)-C(=O)-, -N(C 1-2 alkyl)-SO2-, -NR y -SO2-, -NH-, -N=4-8 membered heterocycloalkyl-, -N(C 1-3 alkylene-C 3-8 cycloalkyl)-, -N(CO-C 2-6 alkenyl)-, -N(CO-C 2-6 alkynyl)-, -N(SO2-C 2-6 alkenyl)-, -N(CO-CH=C 4-6 cycloalkyl)-, -N(CO-C 3-6 cycloalkyl)-, -N(CO-C 4-6 heterocycloalkyl)-, -N(CO-(5-6 membered heteroaryl))-, 3-4 cycloalkyl-(5-6 membered heteroaryl))-, y -C(=O)C 1-6 alkyl)-, -N(-NR y -SO2C 1-6 alkyl)-, -N(-NR y -CN)-, -N(C 3-6 cycloalkyl)-, -N(4-6 membered heterocycloalkyl)-, -N(SO2-C 3-6 cycloalkyl)-, -NR y -C(=O)O-, -NR y -C(=O)NH-, -OC(=O)-, or -N(SO2C 1-6 alkyl)-, -N(C 2-4 haloalkenyl)-, -N(SO2-4 membered heterocycloalkyl)-, -N(SO2-5 membered heteroaryl)-, -N(C 1-4 alkyl)-, said alkylene, alkenylene, alkynylene, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, -NH optionally substituted with 1-5 R x substituted; L 21 -OC(=O)-, -Se-, -NHC(O)O-CH2-, R y selected from D, C 1-2 alkyl, C 1-2 alkoxy, deuterated C 1-2 alkyl, halogenated C 1-2 alkyl, C 3-6 cycloalkyl.

5. The compound, stereoisomer, or pharmaceutically acceptable salt thereof according to any one of claims 1-4, selected from the compounds described in Table I or Table II.

6. A pharmaceutical composition comprising a compound, stereoisomer, or pharmaceutically acceptable salt thereof according to any one of claims I-5, and one or more pharmaceutically acceptable carriers and / or excipients.

7. The pharmaceutical composition according to claim 6, comprising 1-1500 mg of a compound, stereoisomer, or pharmaceutically acceptable salt thereof according to any one of claim 1-5, and one or more pharmaceutically acceptable carriers and / or excipients.

8. Use of a compound, stereoisomer, or pharmaceutically acceptable salt thereof according to any one claims 1-5, or a pharmaceutical composition according to claim 6 or 7, for the manufacture of a medicament for the treatment / prevention of a VAV1 mediated disease.

9. The use according to claim 8, wherein the VAV1 mediated disease is selected from autoimmune diseases, preferably rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease.

10. A method for treating a disease in a mammal, the method comprising administering to the subject a therapeutically effective amount of a compound, stereoisomer, or pharmaceutically acceptable salt thereof according to any one claim 1-5, or a pharmaceutical composition according to claim 6 or 7, wherein the therapeutically effective amount is 1-1500 mg, and the disease is selected from autoimmune diseases, preferably rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease.

Images